Cross Country Healthcare (CCRN) 10-Q 3 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 31, 2017
Document and Entity Information [Abstract]
Trading Symbol	CCRN
Entity Registrant Name	CROSS COUNTRY HEALTHCARE INC
Entity Central Index Key	1,141,103
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding		36,480,911

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 10,765	$ 20,630
Accounts receivable, net of allowances of $3,616 in 2017 and $3,245 in 2016	181,608	173,620
Prepaid expenses	5,142	6,126
Insurance recovery receivable	2,813	3,037
Other current assets	1,654	2,198
Total current assets	201,982	205,611
Property and equipment, net of accumulated depreciation of $46,386 in 2017 and $43,141 in 2016	14,075	12,818
Goodwill	123,244	79,648
Trade names	35,402	35,402
Other intangible assets, net	62,763	36,835
Other non-current assets	19,190	18,064
Total assets	456,656	388,378
Current liabilities:
Accounts payable and accrued expenses	55,034	58,837
Accrued compensation and benefits	32,039	33,243
Other current liabilities	7,146	5,012
Total current liabilities	94,219	97,092
Long-term debt and capital lease obligations, less current portion	95,331	84,760
Non-current deferred tax liabilities	14,763	13,154
Long-term accrued claims	30,695	28,870
Contingent consideration	4,618	5,301
Other long-term liabilities	7,682	7,399
Total liabilities	247,308	236,576
Commitments and contingencies
Stockholders' equity:
Common stock	4	3
Additional paid-in capital	304,957	256,570
Accumulated other comprehensive loss	(1,198)	(1,241)
Accumulated deficit	(95,061)	(104,089)
Total Cross Country Healthcare, Inc. stockholders' equity	208,702	151,243
Noncontrolling interest in subsidiary	646	559
Total stockholders' equity	209,348	151,802
Total liabilities and stockholders' equity	$ 456,656	$ 388,378

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 3,616	$ 3,245
Property and equipment, accumulated depreciation	$ 46,386	$ 43,141

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Revenue from services	$ 228,488,000	$ 214,988,000	$ 645,374,000	$ 611,014,000
Operating expenses:
Direct operating expenses	168,008,000	156,778,000	475,091,000	446,912,000
Selling, general and administrative expenses	47,346,000	45,922,000	141,182,000	133,530,000
Bad debt expense	433,000	19,000	1,082,000	496,000
Depreciation and amortization	2,849,000	2,092,000	7,325,000	6,969,000
Acquisition-related contingent consideration	(605,000)	237,000	(54,000)	707,000
Acquisition and integration costs	1,366,000	0	1,953,000	0
Restructuring costs	724,000	611,000	724,000	611,000
Impairment charges	0	0	0	24,311,000
Total operating expenses	220,121,000	205,659,000	627,303,000	613,536,000
Income (loss) from operations	8,367,000	9,329,000	18,071,000	(2,522,000)
Other expenses (income):
Interest expense	1,221,000	1,435,000	2,975,000	4,678,000
Gain on derivative liability	0	(7,105,000)	(1,581,000)	(19,970,000)
Loss on early extinguishment of debt	0	0	4,969,000	1,568,000
Other income, net	(57,000)	(92,000)	(116,000)	(143,000)
Income before income taxes	7,203,000	15,091,000	11,824,000	11,345,000
Income tax expense (benefit)	159,000	802,000	1,278,000	(5,035,000)
Consolidated net income	7,044,000	14,289,000	10,546,000	16,380,000
Less: Net income attributable to noncontrolling interest in subsidiary	321,000	223,000	983,000	529,000
Net income attributable to common shareholders	$ 6,723,000	$ 14,066,000	$ 9,563,000	$ 15,851,000
Net income per share attributable to common shareholders - Basic (in dollars per share)	$ 0.19	$ 0.44	$ 0.28	$ 0.49
Net income (loss) per share attributable to common shareholders - Diluted (in dollars per share)	$ 0.19	$ 0.22	$ 0.24	$ (0.04)
Weighted average common shares outstanding:
Basic (shares)	35,748	32,221	34,768	32,088
Diluted (shares)	36,036	36,255	36,179	36,215

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement of Comprehensive Income [Abstract]
Consolidated net income	$ 7,044	$ 14,289	$ 10,546	$ 16,380
Other comprehensive (loss) income, before income tax:
Unrealized foreign currency translation (loss) gain	(15)	15	43	(12)
Other comprehensive (loss) income, net of tax	(15)	15	43	(12)
Comprehensive income	7,029	14,304	10,589	16,368
Less: Net income attributable to noncontrolling interest in subsidiary	321	223	983	529
Comprehensive income attributable to common shareholders	$ 6,708	$ 14,081	$ 9,606	$ 15,839

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash flows from operating activities
Consolidated net income	$ 10,546,000	$ 16,380,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	7,325,000	6,969,000
Provision for allowances	3,071,000	3,270,000
Deferred income tax expense (benefit)	1,609,000	(5,889,000)
Gain on derivative liability	(1,581,000)	(19,970,000)
Impairment charges	0	24,311,000
Loss on early extinguishment of debt	4,969,000	1,568,000
Equity compensation	3,083,000	2,614,000
Other non-cash costs	508,000	1,983,000
Changes in operating assets and liabilities:
Accounts receivable	3,337,000	(3,571,000)
Prepaid expenses and other assets	1,111,000	(1,036,000)
Accounts payable and accrued expenses	(5,255,000)	5,634,000
Other liabilities	(18,000)	6,000
Net cash provided by operating activities	28,705,000	32,269,000
Cash flows from investing activities
Acquisitions, net of cash acquired	(85,977,000)	0
Acquisition-related settlements	(239,000)	(1,858,000)
Purchases of property and equipment	(4,043,000)	(5,024,000)
Proceeds from sale of business	0	500,000
Net cash used in investing activities	(90,259,000)	(6,382,000)
Cash flows from financing activities
Proceeds from Term Loans	62,000,000	40,000,000
Principal payments on Term Loans	(1,500,000)	(30,500,000)
Convertible Note cash payment	(5,000,000)	0
Borrowings on revolving credit facility	39,000,000	57,200,000
Repayments on revolving credit facility	(39,000,000)	(65,200,000)
Debt issuance costs	(901,000)	(1,182,000)
Extinguishment fees	(578,000)	(641,000)
Other	(2,350,000)	(1,293,000)
Net cash provided by (used in) financing activities	51,671,000	(1,616,000)
Effect of exchange rate changes on cash	18,000	(17,000)
Change in cash and cash equivalents	(9,865,000)	24,254,000
Cash and cash equivalents at beginning of period	20,630,000	2,453,000
Cash and cash equivalents at end of period	$ 10,765,000	$ 26,707,000

EARNINGS PER SHARE - Additional

EARNINGS PER SHARE - Additional Information - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Dilutive convertible notes (shares)	0	3,521,126	967,342	3,521,126

ORGANIZATION AND BASIS OF PRESE

ORGANIZATION AND BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the Company). The condensed consolidated financial statements include all assets, liabilities, revenue, and expenses of Cross Country Talent Acquisition Group, LLC (formerly InteliStaf of Oklahoma, LLC), which is controlled by the Company but not wholly-owned. The Company records the ownership interest of the noncontrolling shareholder as noncontrolling interest in subsidiary. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, all entries necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. These entries consisted of all normal recurring items. The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles (U.S. GAAP) for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December 31, 2017 . These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission. The December 31, 2016 condensed consolidated balance sheet included herein was derived from the December 31, 2016 audited consolidated balance sheet included in the Company’s Annual Report on Form 10-K.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Significant estimates and assumptions are used for, but not limited to: (1) the valuation of accounts receivable; (2) goodwill, trade names, and other intangible assets; (3) other long-lived assets; (4) share-based compensation; (5) accruals for health, workers’ compensation and professional liability claims; (6) valuation of deferred tax assets; (7) purchase price allocation; (8) derivative liability; (9) legal contingencies; (10) contingent considerations; (11) income taxes; and (12) sales and other non-income tax liabilities. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. Actual results could differ from those estimates. Restructuring Costs During the three and nine months ended September 30, 2017, the Company incurred a restructuring charge of $0.7 million related to a cost savings initiative, which consisted of $0.5 million in post-employment benefits and $0.2 million of exit liabilities related to lease consolidations. During the three and nine months ended September 30, 2017, the Company paid $0.3 million relating to its restructuring liability, related primarily to postemployment benefits. As of September 30, 2017, the balance in the accrued restructuring liability was $0.6 million , which was comprised of $0.4 million (including $0.2 million related to a prior initiative) of post-employment benefits and $0.2 million of exit liabilities. Recently Adopted Accounting Pronouncements In August 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments , which amends the guidance in ASC 230 on the classification of certain cash receipts and payments in the statement of cash flows. This update intended to reduce the diversity that has resulted from the lack of consistent principles on this topic by adding or clarifying guidance on eight cash flow issues, including: debt prepayment or debt extinguishment costs, contingent consideration payments made after a business combination, and separately identifiable cash flows and application of the predominance principle. ASU 2016-15 is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. Early adoption was permitted. The Company elected to early adopt this standard in its first quarter of 2017, applying the guidance retrospectively with no material impact on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting. The Company adopted this guidance in the first quarter of 2017. ASU 2016-09 eliminates the requirement to delay the recognition of excess tax benefits until they reduce current taxes payable. Required method of adoption is modified retrospective transition method. Upon adoption, previously unrecognized excess tax benefits of $1.3 million had no impact on the Company's accumulated deficit balance as the related deferred tax assets were fully offset by a valuation allowance. ASU 2016-09 also requires excess tax benefits and deficiencies to be recognized prospectively in the provision for income taxes rather than additional paid-in capital. As a result of the adoption, the Company's provision for income taxes was not impacted due to its full valuation allowance. Additionally, as permitted by the ASU, the Company elected to account for forfeitures as they occur rather than estimate expected forfeitures using a modified retrospective transition method. As a result, the Company recorded a cumulative-effect adjustment of $0.5 million to accumulated deficit and lower share-based compensation expense of less than $0.1 million compared to the amount of expense that would have been recorded for its first three quarters of 2017. Under ASU 2016-09, the threshold for awards to qualify for equity treatment permits withholding up to the maximum statutory tax rates in the applicable jurisdictions. Prior to the adoption of ASU 2016-09, the Company did not allow an award to be partially settled in cash in excess of the minimum statutory withholding requirements. Subsequent to the adoption of the standard, the Company will allow awards to be partially settled at the maximum applicable statutory rates. Finally, ASU 2016-09 requires excess tax benefits to be presented as a component of operating cash flows rather than financing cash flows. The Company elected to adopt this requirement prospectively and accordingly, prior periods have not been adjusted. Excess tax benefits were not material for all periods presented. In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments , to clarify the steps required to assess whether a call or put option meets the criteria for bifurcation as an embedded derivative. ASU 2016-06 is effective for interim and annual periods beginning after December 15, 2016, and requires a modified retrospective approach to adoption. The Company adopted this guidance in the first quarter of 2017. The adoption of this guidance had no impact on the Company's results of operations.

ACQUISITIONS

ACQUISITIONS	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
ACQUISITIONS	ACQUISITIONS Advantage RN Effective July 1, 2017, the Company acquired all of the assets of Advantage RN, LLC and its subsidiaries (collectively, Advantage) for cash consideration of $86.6 million , net of cash acquired. The total purchase price of $88.0 million was subject to a net working capital reduction of $0.6 million at the closing and an additional $0.8 million was received during the third quarter as the final adjustment for net working capital. Additionally, $0.6 million of the purchase price was deferred as of the closing and is due the seller within 20 months, less any Cobra and healthcare payments incurred by the Company on behalf of the seller. As of September 30, 2017, approximately $0.3 million has been paid for claims and the remaining $0.3 million liability is included in other current and long-term liabilities on the Company’s balance sheet. Included in the amount paid at closing were two escrow accounts, the first was $14.5 million which related to tax liabilities and the second was $7.5 million which was to cover any post-close liabilities. On July 28, 2017, $7.3 million related to the tax liabilities was released from escrow, leaving a balance of $7.2 million . The Company financed the purchase using $19.9 million in available cash and $66.9 million in borrowing under its Credit Facility, including a $40.0 million incremental term loan, which was subsequently refinanced on August 1, 2017. See Note 7 - Debt for further information. The transaction will be treated as a purchase of assets for income tax purposes. Advantage is primarily a travel nurse staffing company that deploys many of its nurses through Managed Service Providers (MSP) and Vendor Management Systems, and Advantage maintains direct relationships with many hospitals throughout the United States. This was a strategic acquisition to help the Company fill its recent MSP contract wins, and for revenue growth. The acquisition has been accounted for in accordance with FASB ASC 805, Business Combinations , using the acquisition method of accounting. As such, the results of Advantage from July 1, 2017 are included in the Company's consolidated statement of operations and were: revenue of $24.5 million and contribution income, as defined in Note 11 - Segment Data, of $2.1 million . The acquisition results have been substantially aggregated with the Company's Nurse and Allied Staffing business segment, with less than 2% of the business included in the Physician Staffing business segment. See Note 11 - Segment Data. The following is the estimated fair value of the purchase price for Advantage on July 1, 2017: (amounts in thousands) Purchase price $ 88,000 Net working capital adjustments (1,438 ) Cash consideration 86,562 Cash acquired 2,833 Total funds disbursed $ 89,395 The purchase price was allocated to the assets acquired and the liabilities assumed based on the estimated fair value at the date of acquisition. The Company used a third-party appraiser to assist with the determination of the fair value and estimated useful lives of certain acquired assets and liabilities. These estimates are preliminary; however, the Company does not expect there to be material differences upon the finalization of the purchase price allocation. The following table is an estimate of the fair value of the assets acquired and liabilities assumed on July 1, 2017. (amounts in thousands) Cash and cash equivalents $ 2,833 Accounts receivable 14,396 Other current assets 392 Property and equipment 333 Goodwill 43,596 Other intangible assets 29,900 Total assets acquired 91,450 Accounts payable and accrued expenses 368 Accrued employee compensation and benefits 1,685 Other current liabilities 2 Total liabilities assumed 2,055 Net assets acquired $ 89,395 The Company assigned the following values to other identifiable intangible assets: $4.5 million to trade names with a weighted average estimated useful life of 10 years , $13.8 million to customer relationships with a weighted average estimated useful life of 10 years , $11.3 million to a database, consisting of healthcare professionals, with a weighted average estimated useful life of 10 years , and $0.3 million to non-compete agreements with a weighted average estimated useful life of 5 years , for a total of $29.9 million in definite life intangible assets with a weighted average estimated useful life of 10 years . The remaining excess purchase price over the fair value of net assets acquired of $43.6 million was recorded as goodwill, which is expected to be deductible for tax purposes. Associated acquisition-related costs incurred were $1.4 million and have been included in acquisition and integration costs on the Company's condensed consolidated statement of operations for the three months ended September 30, 2017. US Resources Healthcare On December 1, 2016, the Company completed the acquisition of a recruitment process outsourcing business, US Resources Healthcare, LLC (USR). This acquisition expands the Company's workforce solutions offerings to deliver financial and operating efficiencies through labor optimization services while enhancing the quality of care. The agreement specified that the sellers were eligible to receive additional purchase price consideration of $4.5 million , with a maximum of $1.0 million for 2017, $2.0 million for 2018, and $1.5 million for 2019, based on attainment of specific performance criteria achieved in each of those years. As of September 30, 2017, the fair value of the remaining obligations was estimated at $1.5 million and is included in other current liabilities and contingent consideration on the condensed consolidated balance sheets. See Note 9 - Fair Value Measurements. The acquisition was deemed immaterial and has been accounted for in accordance with the Business Combinations Topic of the FASB ASC, using the acquisition method of accounting. USR's results of operations are included in the consolidated statements of operations from December 1, 2016 and have been included in the Company's Nurse and Allied Staffing business segment. See Note 6 - Goodwill, Trade Names, and Other Intangible Assets and Note 9 - Fair Value Measurements. Mediscan On October 30, 2015, the Company completed the acquisition of all of the membership interests of New Mediscan II, LLC, Mediscan Diagnostic Services, LLC, and Mediscan Nursing Staffing, LLC (collectively, Mediscan). In the first quarter of 2016, a net working capital adjustment of $0.3 million was settled. Additionally, an amount of $5.0 million of the purchase price that was held in escrow to cover any post-closing liabilities, was released to the sellers on May 3, 2017. The agreement also specified that the sellers were eligible to receive additional purchase price consideration of $7.0 million , with $3.5 million per year based on attainment of specific performance criteria in 2016 and 2017. As of December 31, 2016, the Company determined that the first year earnout was not achieved for 2016 and, as of September 30, 2017, the Company determined that the second year earnout would not be achieved for 2017. In connection with the Mediscan acquisition, the Company also assumed additional contingent purchase price liabilities for a previously acquired business that are payable annually based on specific performance criteria for the 2016 through 2019 years. Payments related to the 2016 through 2018 years are limited to $0.3 million per year and 2019 is uncapped. During the nine months ended September 30, 2017, the Company paid $0.3 million . As of September 30, 2017, the fair value of the remaining obligations was estimated at $3.8 million and is included in other current liabilities and contingent consideration on the condensed consolidated balance sheets. See Note 9 - Fair Value Measurements. Medical Staffing Network On June 30, 2014, the Company acquired substantially all of the assets and certain liabilities of Medical Staffing Network Healthcare, LLC (MSN). Of the purchase price, $2.5 million was deferred and due to the seller 21 months from the acquisition date, less any COBRA expenses incurred by the Company on behalf of former MSN employees over that period. The Company incurred $0.4 million in COBRA expenses since the MSN acquisition and, on April 1, 2016, released to the seller the remaining liability of $2.1 million . Pro Forma Financial Information The following unaudited pro forma financial information approximates the consolidated results of operations of the Company as if the Advantage acquisition had occurred as of January 1, 2016, after giving effect to certain adjustments, including additional interest expense on the amount the Company borrowed on the date of the transaction, the amortization of acquired intangible assets, and the elimination of certain expenses that will not be recurring in post-acquisition periods, net of an estimated income tax impact. These adjustments include removing transaction-related expenses of approximately $2.0 million for the nine months ended September 30, 2017. These results are not necessarily indicative of future results as they do not include incremental investments in support functions, elimination of costs for integration or operating synergies, or an estimate of any impact on interest expense resulting from the operating cash flow of the acquired business, among other adjustments that could be made in the future but are not factually supportable on the date of the transaction. Nine Months Ended September 30, 2017 September 30, 2016 (unaudited, amounts in thousands except per share data) Revenue from services $ 696,475 $ 685,749 Net income attributable to common shareholders $ 13,165 $ 18,096 Net income per share attributable to common shareholders - Basic $ 0.38 $ 0.56 Net income per share attributable to common shareholders - Diluted $ 0.34 $ 0.02

EARNINGS PER SHARE

EARNINGS PER SHARE	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
EARNINGS PER SHARE	EARNINGS PER SHARE The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share: Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 (amounts in thousands, except per share data) Numerator: Net income attributable to common shareholders - Basic $ 6,723 $ 14,066 $ 9,563 $ 15,851 Interest on Convertible Notes — 853 695 2,529 Gain on derivative liability — (7,105 ) (1,581 ) (19,970 ) Net income (loss) attributable to common shareholders - Diluted $ 6,723 $ 7,814 $ 8,677 $ (1,590 ) Denominator: Weighted average common shares - Basic 35,748 32,221 34,768 32,088 Effective of diluted shares: Share-based awards 288 513 444 606 Convertible Notes — 3,521 967 3,521 Weighted average common shares - Diluted 36,036 36,255 36,179 36,215 Net income per share attributable to common shareholders - Basic $ 0.19 $ 0.44 $ 0.28 $ 0.49 Net income (loss) per share attributable to common shareholders - Diluted $ 0.19 $ 0.22 $ 0.24 $ (0.04 ) For the periods presented, no tax benefits have been assumed in the weighted average share calculation due to a full valuation allowance on the Company's deferred tax assets. The Convertible Notes were paid in full on March 17, 2017. Applying the if-converted method, 967,342 shares were included in diluted weighted average shares for the nine months ended September 30, 2017 and 3,521,126 shares were included for the three and nine months ended September 30, 2016 because their effect was dilutive.

COMPREHENSIVE INCOME (LOSS)

COMPREHENSIVE INCOME (LOSS)	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
COMPREHENSIVE INCOME (LOSS)	COMPREHENSIVE INCOME (LOSS) Total comprehensive income (loss) includes net income or loss and foreign currency translation adjustments, net of any related deferred taxes. Certain of the Company’s foreign subsidiaries use their respective local currency as their functional currency. In accordance with the Foreign Currency Matters Topic of the FASB ASC, assets and liabilities of these operations are translated at the exchange rates in effect on the balance sheet date. Income statement items are translated at the average exchange rates for the period. The cumulative impact of currency fluctuations related to the balance sheet translation is included in accumulated other comprehensive loss in the accompanying condensed consolidated balance sheets and was approximately $1.2 million at both September 30, 2017 and December 31, 2016 . There was no income tax impact related to foreign currency translation adjustments for the three and nine month periods ended September 30, 2017 and September 30, 2016 .

GOODWILL, TRADE NAMES, AND OTHE

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS	GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS The Company had the following acquired intangible assets: September 30, 2017 December 31, 2016 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount (amounts in thousands) Intangible assets subject to amortization: Databases $ 42,909 $ 17,952 $ 24,957 $ 31,609 $ 16,147 $ 15,462 Customer relationships 55,524 25,091 30,433 41,724 23,316 18,408 Non-compete agreements 3,919 3,574 345 3,619 3,527 92 Trade names 7,716 688 7,028 3,216 343 2,873 Other intangible assets, net $ 110,068 $ 47,305 $ 62,763 $ 80,168 $ 43,333 $ 36,835 Intangible assets not subject to amortization: Trade names 35,402 35,402 $ 98,165 $ 72,237 As of September 30, 2017 , estimated annual amortization expense is as follows: Years Ending December 31: (amounts in thousands) 2017 $ 1,785 2018 7,168 2019 7,132 2020 7,027 2021 6,819 Thereafter 32,832 $ 62,763 The Company's carrying amount of goodwill by segment is as follows: Nurse Physician Other Human Total (amounts in thousands) Balances as of December 31, 2016 Aggregate goodwill acquired $ 304,277 $ 43,405 $ 9,418 $ 357,100 Accumulated impairment loss (259,732 ) (17,720 ) — (277,452 ) Goodwill, net of impairment loss 44,545 25,685 9,418 79,648 Changes to aggregate goodwill in 2017 Goodwill acquired (a) 43,596 — — 43,596 Balances as of September 30, 2017 Aggregate goodwill acquired 347,873 43,405 9,418 400,696 Accumulated impairment loss (259,732 ) (17,720 ) — (277,452 ) Goodwill, net of impairment loss $ 88,141 $ 25,685 $ 9,418 $ 123,244 _______________ (a) Goodwill acquired from the acquisition of Advantage. See Note 3 - Acquisitions. As of September 30, 2017, the Company performed a qualitative assessment of each of its reporting units and determined it was less-likely-than-not that the fair value of its reporting units dropped below their carrying value. As a result, management concluded that no impairment testing was warranted as of September 30, 2017. Although management believes that the Company's current estimates and assumptions are reasonable and supportable, there can be no assurance that the estimates and assumptions made for purposes of the impairment testing will prove to be accurate predictions of future performance. The Company will conduct its annual impairment test of goodwill and other indefinite-lived intangible assets in the fourth quarter of 2017. During an evaluation of goodwill and other identified intangible assets at June 30, 2016, the Company determined that indicators were present in the Physician Staffing reporting unit which would suggest the fair value of the reporting unit may have declined below the carrying value. The evaluation resulted in the carrying value of goodwill and other intangible assets for Physician Staffing to exceed the estimated fair value. As a result, the Company recorded pre-tax impairment charges totaling $24.3 million with $17.7 million related to goodwill, $0.6 million related to trade names, and $6.0 million related to customer relationships.

DEBT

DEBT	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
DEBT	DEBT The Company's long-term debt consists of the following: September 30, 2017 December 31, 2016 Principal Unamortized Discount and Debt Issuance Costs Principal Unamortized Discount and Debt Issuance Costs (amounts in thousands) Term Loan, interest 3.49% and 2.62% at September 30, 2017 and December 31, 2016, respectively $ 100,000 $ (923 ) $ 39,500 $ (363 ) Convertible Notes, fixed rate interest of 8.00% — — 25,000 (4,669 ) Convertible Notes derivative liability — — 27,532 — Capital lease obligations 12 — 23 — Total debt 100,012 (923 ) 92,055 (5,032 ) Less current portion (3,758 ) — (2,263 ) — Long-term debt $ 96,254 $ (923 ) $ 89,792 $ (5,032 ) As of September 30, 2017 , the aggregate scheduled maturities of the term loan are as follows: Term Loan (amounts in thousands) Through Years Ending December 31: 2017 $ — 2018 6,875 2019 7,500 2020 8,125 2021 10,000 Thereafter 67,500 Total $ 100,000 Amendment and Restatement of Senior Credit Facility On August 1, 2017, the Company entered into an Amendment and Restatement of its Credit Agreement dated June 22, 2016 (Amended and Restated Credit Agreement), to refinance and increase the current aggregate committed size of the facility to $215.0 million , including a term loan of $100.0 million (Amended Term Loan) and a $115.0 million revolving credit facility (Amended Revolving Credit Facility) (together with the Amended Term Loan, the Amended Credit Facilities). The Amended Revolving Credit Facility includes a subfacility for swingline loans up to an amount not to exceed $15.0 million , and a $35.0 million sublimit for the issuance of standby letters of credit. The proceeds of $106.5 million from this refinancing included $6.5 million under the new revolving credit facility and were used to repay borrowings under the Company’s 2016 Senior Credit Facilities (as defined below), as well as to pay related interest, fees, and expenses of the transaction. In addition to increasing the size of the facilities, the maturity date was extended to July 31, 2022. The Amended and Restated Credit Agreement also includes an accordion feature permitting the Company, subject to certain conditions, to increase the aggregate amount of the commitments under the Amended Revolving Credit Facility or establish one or more additional term loans in an aggregate amount not to exceed $50.0 million with optional additional commitments from existing lenders or new commitments from additional lenders. Other terms and pricing are substantially similar to the 2016 Credit Agreement (as defined below). Borrowings under the Amended Term Loan are payable in quarterly installments, commencing January 2, 2018, in an aggregate per annum amount equal to 5% for the first four installments, 7.5% for the next eight installments, and 10% for the remaining installments; provided that, to the extent not previously paid, the aggregate unpaid principal balance would be due and payable on the maturity date. Subject to the Amended and Restated Credit Agreement, the Company pays interest on (i) each Base Rate Loan at the Base Rate (as defined therein) plus the Applicable Margin in effect from time to time, (ii) each LIBOR Index Rate Loan at the One Month LIBOR Index Rate (as defined therein) plus the Applicable Margin in effect from time to time and (iii) each Eurodollar Loan at the Adjusted LIBOR for the applicable Interest Period (as defined therein) in effect for such Loan plus the Applicable Margin in effect from time to time. The Applicable Margin, as of any date, is a percentage per annum determined by reference to the applicable Consolidated Net Leverage Ratio (as defined by the agreement) in effect on such date as set forth in the table below. Level Consolidated Net Leverage Ratio Eurodollar Loans, LIBOR Index Rate Loans and Letter of Credit Fee Base Rate Loans Commitment Fee I Less than 1.50:1.00 1.75% 0.75% 0.25% II Greater than or equal to 1.50:1.00 2.00% 1.00% 0.30% III Greater than or equal to 2.00:1.00 2.25% 1.25% 0.30% IV Greater than or equal to 2.50:1.00 2.50% 1.50% 0.35% V Greater than or equal to 3.00:1.00 2.75% 1.75% 0.40% As of September 30, 2017 , the Amended Term Loan and Amended Revolving Credit Facility bore interest at a rate equal to One Month LIBOR plus 2.25% . The interest rate is subject to an increase of 2.00% if an event of default exists under the Amended and Restated Credit Agreement. The Company is required to pay a commitment fee on the average daily unused portion of the Amended Revolving Credit Facility, based on the Applicable Margin which is 0.30% as of September 30, 2017 . The Company has the right at any time and from time to time to prepay any borrowing, in whole or in part, without premium or penalty, by giving irrevocable written notice (or telephonic notice promptly confirmed in writing) except that such notice shall be revocable if a prepayment is being made in anticipation of concluding a financing arrangement, and the Company is ultimately unable to secure such financing arrangement. The Company is required to prepay the Amended Credit Facilities under certain circumstances including from net cash proceeds from asset sales or dispositions in excess of certain thresholds, as well as from net cash proceeds from the issuance of certain debt by the Company. The Amended and Restated Credit Agreement contains customary representations, warranties, and affirmative covenants. The Amended and Restated Credit Agreement also contains customary negative covenants, subject to some exceptions, on (i) indebtedness and preferred equity, (ii) liens, (iii) fundamental changes, (iv) investments, (v) restricted payments, and (vi) sale of assets and certain other restrictive agreements. The Amended and Restated Credit Agreement also contains customary events of default, such as payment defaults, cross-defaults to other material indebtedness, bankruptcy and insolvency, the occurrence of a defined change in control and the failure to observe the negative covenants and other covenants related to the operation of the Company’s business. The Amended and Restated Credit Agreement also includes two financial covenants: (i) limiting a maximum Consolidated Total Leverage ratio (as defined therein) to be no greater than 3.50 :1.00 for the fiscal quarters ending September 30, 2017 through June 30, 2018, 3.25 :1.00 for the fiscal quarters ending September 30, 2018 through June 30, 2019, and 3.00 :1.00 for each fiscal quarter ending thereafter and as adjusted pursuant to a Qualified Permitted Acquisition (as defined therein); and (ii) requiring a minimum Consolidated Fixed Charge Coverage ratio (as defined therein) as of the end of each fiscal quarter of 1.50 :1.00. As of September 30, 2017 , the Company was in compliance with the financial covenants and other covenants contained in the Amended and Restated Credit Agreement. The obligations under the Amended and Restated Credit Agreement are guaranteed by all of the Company’s domestic wholly-owned subsidiaries and are secured by a first-priority security interest in the Collateral (as defined therein). As of September 30, 2017 , the Company has $21.6 million letters of credit outstanding and $93.4 million available under the Amended Revolving Credit Facility. The letters of credit relate to the Company’s workers’ compensation and professional liability insurance policies. 2016 Senior Credit Facilities On June 22, 2016, the Company entered into a senior credit agreement ( 2016 Credit Agreement), which provided for an initial term loan of $40.0 million (Term Loan) and a revolving credit facility of up to $100.0 million (Revolving Credit Facility) (together with the Term Loan, the 2016 Senior Credit Facilities) both of which would have matured on June 22, 2021. The Revolving Credit Facility included a subfacility for swingline loans up to an amount not to exceed $15.0 million , and a $35.0 million sublimit for the issuance of standby letters of credit. Proceeds of the Senior Credit Facilities were used primarily to refinance the Company’s First Lien Loan and Second Lien Term Loan (see Prior Credit Facilities) and to pay related transaction fees and expenses, including a prepayment penalty of $0.6 million . The repayment of the Second Lien Term Loan was treated as extinguishment of debt and, as a result, the Company recognized a loss on extinguishment of debt of approximately $1.6 million in the second quarter of 2016, related to the write-off of unamortized net debt discount and issuance costs as well as transaction fees and expenses. On July 5, 2017, the Company entered into a Second Amendment to its 2016 Credit Agreement primarily to allow for the acquisition of Advantage including a reset of the Applicable Margin to Level III, based on the incremental borrowings and consistent with the prior pricing grid (or 2.25% for Eurodollar Loans and LIBOR Index Rate Loans, 1.25% for Base Rate Loans and a 0.30% commitment fee). Also, on July 5, 2017, the Company entered into an Incremental Term Loan Agreement for $40.0 million with SunTrust as Lender and Administrative Agent to pay for part of the consideration of the acquisition of Advantage. The Incremental Term Loan maturity date was June 22, 2021 and was prepayable at any time without penalty. Borrowings under the Incremental Term Loan were payable in quarterly installments, commencing September 30, 2017, with each such installment being in the aggregate principal amount (subject to adjustment as a result of prepayments) for the first eight installments equal to 1.875% and 2.5% of the principal amount of the Incremental Term Loan for the remaining installments; provided that, to the extent not previously paid, the aggregate unpaid principal balance would be due and payable on the maturity date. As of July 5, 2017 the Applicable Margin for Eurodollar Loans and LIBOR Index Rate Loans was 2.25% and the Applicable Margin for Base Rate Loans was 1.25% . Convertible Notes The Company and certain of its domestic subsidiaries entered into a Convertible Note Purchase Agreement (the Note Purchase Agreement), with certain note holders (collectively, the Noteholders) on June 30, 2014. Pursuant to the Note Purchase Agreement, the Company sold to the Noteholders an aggregate of $25.0 million of convertible notes (the Convertible Notes). On March 17, 2017, the Company paid in full the Convertible Notes. In connection with the repayment, the Company issued to the Noteholders an aggregate of 3,175,584 shares of Common Stock, par value $0.0001 , and cash in the aggregate amount of $5.6 million (of which $5.0 million is included in repayment of debt and $0.6 million is presented as extinguishment fees, both within financing activities on the condensed consolidated statements of cash flows). Upon derecognition of the net carrying amounts of the Convertible Notes (the remaining $20.0 million after the $5.0 million cash payment) and derivative liability ( $26.0 million ), the Company recognized a non-cash charge of $5.0 million as loss on early extinguishment and a non-cash addition to additional paid-in capital of $46.0 million for the fair value of the shares, which is not presented on the condensed consolidated statements of cash flows. The loss on early extinguishment of debt includes the write-off of unamortized loan fees and remaining interest due through the Forced Conversion date (defined below) of June 30, 2017. The Convertible Notes were convertible at the option of the holders thereof at any time into shares of the Common Stock at a conversion price of $7.10 per share, or 3,521,126 shares of Common Stock. After three years from the issuance date, the Company had the right to force a conversion of the Convertible Notes if the volume-weighted average price (VWAP) per share of its Common Stock exceeded 125% of the then conversion price for 20 days of a 30 day trading period (Forced Conversion date). The Convertible Notes bore interest at a rate of 8.00% per annum, payable in quarterly cash installments. The Convertible Notes would have matured on June 30, 2020, unless earlier repurchased, redeemed or converted. Subject to certain exceptions, the Company was not permitted to redeem the Convertible Notes until June 30, 2017. Prior Credit Facilities At December 31, 2015, the Company had a senior secured asset-based revolving credit facility (First Lien Loan), with a termination date of June 30, 2017, in the aggregate principal amount of up to $85.0 million , which included a subfacility for swingline loans up to an amount equal to 10% of the aggregate Revolver Commitments, as defined in the agreement, and a $35.0 million subfacility for standby letters of credit. The Company also had a five -year second lien term loan facility (Second Lien Term Loan) in an aggregate principal amount of $30.0 million . The Company had the ability, at its option at any time, to prepay the Second Lien Term Loan in whole or in part at the redemption prices set forth therein, which ranged from 103% of the principal amount thereof for prepayments during the period July 1, 2015 through June 30, 2016, 102% of the principal amount thereof for prepayments during the period July 1, 2016 through June 30, 2017, and 100% of the principal amount thereof for prepayments after June 30, 2017.

CONVERTIBLE NOTES DERIVATIVE LI

CONVERTIBLE NOTES DERIVATIVE LIABILITY	9 Months Ended
	Sep. 30, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
CONVERTIBLE NOTES DERIVATIVE LIABILITY	CONVERTIBLE NOTES DERIVATIVE LIABILITY On March 17, 2017, the Company paid in full its Convertible Notes and, as a result, derecognized the derivative liability. See Note 7 - Debt. The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company issued Convertible Notes with features that were either (i) not afforded equity classification, (ii) embody risks not clearly and closely related to host contracts, or (iii) may be net-cash settled by the counterparty. As required by the Accounting for Derivative Financial Instruments and Hedging Activities Topic of the FASB ASC, in certain instances, these instruments were required to be carried as derivative liabilities, at fair value, in the financial statements. The Convertible Notes were subject to anti-dilution adjustments that allowed for the reduction in the Conversion Price, as defined in the agreement, in the event the Company subsequently issued equity securities including Common Stock or any security convertible or exchangeable for shares of Common Stock for a price less than the then current conversion price. In addition, the Convertible Notes allowed the issuer to exercise optional redemption features and the holder to exercise an offer to purchase feature, under certain conditions. The Company accounted for the conversion option in accordance with the Accounting for Derivative Financial Instruments and Hedging Activities Topic. Since this conversion feature is not considered to be solely indexed to the Company’s own stock the derivative was recorded as a liability in the line item long-term debt on the Company's condensed consolidated balance sheets. The Company’s Convertible Notes derivative liability was measured at fair value using a trinomial lattice model. The optional redemption features, along with the offer to purchase features were incorporated into the valuation model. Inputs into the model required estimates, including such items as estimated volatility of the Company's stock, estimated credit risk of the Company, estimated probabilities of change of control and issuance of additional financing, risk-free interest rate, and the estimated life of the financial instruments being fair valued. In addition, since the conversion price contained an anti-dilution adjustment, the probability that the Conversion Price of the Notes would decrease as the share price decreased was incorporated into the valuation calculation. The fair value of the derivative liability was primarily determined by fluctuations in our stock price. In addition, changes in our credit risk profile impacted the fair value determination. These fluctuations resulted in a current period gain or loss that was presented on the condensed consolidated statements of operations as loss (gain) on derivative liability.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The Fair Value Measurements and Disclosures Topic of the FASB ASC defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Fair Value Measurements and Disclosures Topic also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1 —Quoted prices in active markets for identical assets or liabilities. Level 2 —Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 —Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Items Measured at Fair Value on a Recurring Basis: The Company’s financial assets/liabilities required to be measured on a recurring basis were its: deferred compensation liability included in other long-term liabilities, Convertible Notes derivative liability included in long-term debt and capital lease obligations, and contingent consideration liabilities. Deferred compensation —The Company utilizes Level 1 inputs to value its deferred compensation liability. The Company’s deferred compensation liability is measured using publicly available indices that define the liability amounts, as per the plan documents. Convertible Notes derivative liability —The Company utilized Level 3 inputs to value its Convertible Notes derivative liability. See Note 7 - Debt and Note 8 - Convertible Notes derivative liability. Contingent consideration liabilities —Potential earnout payments related to the acquisition of Mediscan and USR are contingent upon meeting certain performance requirements through 2019. See Note 3 - Acquisitions. The long-term portion of these liabilities is included in contingent consideration, and the short-term portion is included in other current liabilities on the condensed consolidated balance sheets. The Company utilized Level 3 inputs to value these contingent consideration liabilities as significant unobservable inputs were used in the calculation of their fair value. Both of the Mediscan contingent consideration liabilities have been measured at fair value using a discounted cash flow model in a Monte Carlo simulation setting, utilizing significant unobservable inputs, including the expected volatility of the acquisitions' gross profits and an estimated discount rate commensurate with the risks of the expected gross profit stream. In the third quarter of 2017, the Company determined that one of the contingent consideration earnouts related to the Mediscan acquisition would not be achieved for 2017 and, as a result, the entire earnout was reversed. See Note 3 - Acquisitions. The USR contingent consideration is recorded as a liability and measured at fair value using a discounted cash flow model utilizing significant unobservable inputs, including the probability of achieving each of the potential milestones and an estimated discount rate commensurate with the risks of the expected cash flows attributable to the milestones. The fair value of contingent consideration and the associated liabilities will be adjusted to fair value at each reporting date until actual settlement occurs, with the changes in fair value and related accretion reflected as acquisition-related contingent consideration on the condensed consolidated statements of operations. Significant increases (decreases) in the volatility or in any of the probabilities of success, or decreases (increases) in the discount rate would result in a significantly higher (lower) fair value, respectively, and commensurate changes to these liabilities. The table which follows summarizes the estimated fair value of the Company’s financial assets and liabilities measured on a recurring basis: Fair Value Measurements September 30, 2017 December 31, 2016 Financial Liabilities: (amounts in thousands) (Level 1) Deferred compensation $ 1,381 $ 1,472 (Level 3) Convertible Notes derivative liability $ — $ 27,532 Contingent consideration liabilities $ 5,269 $ 5,603 The table which follows reconciles the opening balances to the closing balances for fair value measurements categorized within Level 3 of the fair value hierarchy: Contingent Consideration Convertible Notes Liabilities (a) Derivative Liability (amounts in thousands) December 31, 2016 $ 5,603 $ 27,532 Payments/Settlements (100 ) (25,951 ) Accretion expense 270 — Valuation gain for the period — (1,581 ) March 31, 2017 5,773 — Accretion expense 281 — June 30, 2017 $ 6,054 $ — Payments (180 ) — Accretion expense 209 — Valuation adjustment (814 ) — September 30, 2017 $ 5,269 $ — _______________ (a) Related to the Mediscan acquisition on October 30, 2015 and the USR acquisition on December 1, 2016. Valuation adjustments and accretion expense is included as acquisition-related contingent consideration on the condensed consolidated statements of operations. Items Measured at Fair Value on a Non-Recurring Basis: The Company's non-financial assets, such as goodwill, trade names, other intangible assets, and property and equipment, are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized. As of September 30, 2017 and December 31, 2016, no impairment charges were recognized. Other Fair Value Disclosures: Financial instruments not measured or recorded at fair value in the accompanying condensed consolidated balance sheets consist of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and short and long-term debt. The estimated fair value of accounts receivable, accounts payable and accrued expenses approximate their carrying amount due to the short-term nature of these instruments. The estimated fair value of the Company's debt was calculated using a discounted cash flow analysis and appropriate valuation methodologies using Level 2 inputs from available market information. The following table represents the carrying amounts and estimated fair value of the Company’s significant financial instruments that were not measured at fair value: September 30, 2017 December 31, 2016 Carrying Fair Carrying Fair Financial Liabilities: (amounts in thousands) (Level 2) Term Loan, net $ 99,077 $ 101,000 $ 39,137 $ 41,500 Convertible Notes, net $ — $ — $ 20,331 $ 27,250 Concentration of Risk: The Company has invested its excess cash in highly-rated overnight funds and other highly-rated liquid accounts. The Company has been exposed to credit risk associated with these investments. The Company minimizes its credit risk relating to these positions by monitoring the financial condition of the financial institutions involved and by primarily conducting business with large, well established financial institutions and diversifying its counterparties. The Company generally does not require collateral and mitigates its credit risk by performing credit evaluations and monitoring at-risk accounts. The allowance for doubtful accounts represents the Company’s estimate of uncollectible receivables based on a review of specific accounts and the Company’s historical collection experience. The Company writes off specific accounts based on an ongoing review of collectability as well as past experience with the customer. The Company’s contract terms typically require payment between 15 to 60 days from the date services are provided and are considered past due based on the particular negotiated contract terms. Overall, based on the large number of customers in differing geographic areas, primarily throughout the United States and its territories, the Company believes the concentration of credit risk is limited.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY Stock Repurchase Program During the nine months ended September 30, 2017 and 2016 , the Company did not repurchase any shares of its Common Stock under its February 2008 Board authorization. As of September 30, 2017 , the Company may purchase up to an additional 942,443 shares of Common Stock under the February 2008 Board authorization, subject to certain conditions in the Company's Amended and Restated Credit Agreement. The Company may repurchase up to an aggregate amount not to exceed $2.5 million in any fiscal year, or an unlimited amount if the Company meets certain conditions as described in its Amended and Restated Credit Agreement. At September 30, 2017 , the Company had 35,758,297 shares of Common Stock outstanding. Shares Issued The Company issued 3,175,584 shares to its prior Convertible Notes noteholders. See Note 7 - Debt. Share-Based Payments On May 23, 2017, the Company's shareholders approved an amendment and restatement of its 2014 Omnibus Incentive Plan (2014 Plan), which, among others, included the following modifications: (i) a 2,000,000 share increase of the aggregate share reserve to 6,100,000 shares, (2) extension of the 2014 Plan until May 23, 2027, and (3) re-approval of the Section 162(m) performance goals so that certain incentive awards granted to certain executive officers of the Company may qualify as exempt performance-based compensation. During the nine months ended September 30, 2017 , 323,503 of restricted stock awards and 181,067 targeted performance stock awards were granted under the 2014 Plan to the Company's non-employee directors and management team. The restricted stock awards vest ratably over a three year period and vesting is subject to the employee's continuing employment. The number of shares that are issued for the performance-based stock awards are determined based on the level of attainment of the performance targets. If the minimum level of performance is attained for the 2017 awards, restricted stock will be issued with a vesting date of March 31, 2020, subject to the employee’s continuing employment. During the first quarter of 2017, the Company's Compensation Committee of the Board of Directors approved a 48% level of attainment for the 2016 performance-based share awards, resulting in the issuance of 86,784 performance shares that will vest on December 31, 2018. The following table summarizes restricted stock awards and performance stock awards activity issued under the 2014 Plan for the nine months ended September 30, 2017 : Restricted Stock Awards Performance Stock Awards Number of Weighted Number of Target Weighted Unvested restricted stock awards, January 1, 2017 532,294 $ 9.98 332,092 $ 11.73 Granted 323,503 $ 13.70 181,067 $ 14.36 Vested (292,615 ) $ 8.64 — $ — Forfeited (47,581 ) $ 10.41 (131,016 ) $ 11.78 Unvested restricted stock awards, September 30, 2017 515,601 $ 13.03 382,143 $ 12.96 During the three and nine months ended September 30, 2017 , $1.1 million and $3.1 million , respectively, was included in selling, general and administrative expenses related to share-based payments, and a net of 3,110 and 204,786 shares, respectively, of Common Stock were issued upon the vesting of restricted stock. During the three and nine months ended September 30, 2016 , $0.8 million and $2.6 million , respectively, was included in selling, general and administrative expenses related to share-based payments, and a net of 9,742 and 225,107 shares, respectively, of Common Stock were issued upon the vesting of restricted stock.

SEGMENT DATA

SEGMENT DATA	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
SEGMENT DATA	SEGMENT DATA In accordance with the Segment Reporting Topic of the FASB ASC, the Company reports three business segments – Nurse and Allied Staffing, Physician Staffing, and Other Human Capital Management Services. The Company manages and segments its business based on the services it offers to its customers as described below: ● Nurse and Allied Staffing – Nurse and Allied Staffing provides traditional staffing, recruiting, and value-added workforce solutions including: temporary and permanent placement of travel and local branch-based nurse and allied professionals, MSP services, education healthcare services, and outsourcing services. Its clients include: public and private acute-care and non-acute care hospitals, government facilities, public schools and charter schools, outpatient clinics, ambulatory care facilities, physician practice groups, retailers, and many other healthcare providers throughout the United States. Substantially all of the results of the Advantage acquisition have been aggregated with the Company's Nurse and Allied Staffing business segment. See Note 3 - Acquisitions. ● Physician Staffing – Physician Staffing provides physicians in many specialties, as well as certified registered nurse anesthetists (CRNAs), nurse practitioners (NPs), and physician assistants (PAs) as independent contractors on temporary assignments throughout the U.S. at various healthcare facilities, such as acute and non-acute care facilities, medical group practices, government facilities, and managed care organizations. Less than 2% of the business related to the Advantage acquisition is managed by, and included in, the Physician Staffing business segment. ● Other Human Capital Management Services – Other Human Capital Management Services includes retained and contingent search services for physicians, healthcare executives and other healthcare professionals within the United States. The Company’s management evaluates performance of each segment primarily based on revenue and contribution income. The Company defines contribution income as income or loss from operations before depreciation and amortization, acquisition-related contingent consideration, acquisition and integration costs, restructuring costs, impairment charges, and corporate expenses not specifically identified to a reporting segment. Contribution income is a financial measure used by management when assessing segment performance and is provided in accordance with the Segment Reporting Topic of the FASB ASC. The Company’s management does not evaluate, manage or measure performance of segments using asset information; accordingly, total asset information by segment is not prepared or disclosed. The information in the following table is derived from the segments’ internal financial information as used for corporate management purposes. Certain corporate expenses are not allocated to and/or among the operating segments. Information on operating segments and a reconciliation to income (loss) from operations for the periods indicated are as follows: Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 (amounts in thousands) Revenues: Nurse and Allied Staffing $ 200,492 $ 186,623 $ 564,527 $ 527,436 Physician Staffing 24,871 25,090 71,055 73,470 Other Human Capital Management Services 3,125 3,275 9,792 10,108 $ 228,488 $ 214,988 $ 645,374 $ 611,014 Contribution income: Nurse and Allied Staffing $ 20,663 $ 19,472 $ 54,426 $ 53,877 Physician Staffing 1,340 2,400 4,207 6,003 Other Human Capital Management Services (1 ) (154 ) (200 ) (196 ) 22,002 21,718 58,433 59,684 Unallocated corporate overhead 9,301 9,449 30,414 29,608 Depreciation and amortization 2,849 2,092 7,325 6,969 Acquisition-related contingent consideration (605 ) 237 (54 ) 707 Acquisition and integration costs 1,366 — 1,953 — Restructuring costs 724 611 724 611 Impairment charges — — — 24,311 Income (loss) from operations $ 8,367 $ 9,329 $ 18,071 $ (2,522 )

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Contingencies: Legal Proceedings The Company is subject to legal proceedings and claims that arise in the ordinary course of its business. The Company does not believe the outcome of these matters will have a material adverse effect on the Company's business, financial condition, results of operations or cash flows. Sales and Other State Non-Income Tax Liabilities The Company's sales and other state non-income tax filings are subject to routine audits by authorities in the jurisdictions where it conducts business in the United States which may result in assessments of additional taxes. The Company accrues sales and other non-income tax liabilities based on the Company's best estimate of its probable liability utilizing currently available information and interpretation of relevant tax regulations. Given the nature of the Company's business, significant subjectivity exists as to both whether sales and other state non-income taxes can be assessed on its activity and how the sales tax will ultimately be measured by the relevant jurisdictions. The Company makes a determination for each reporting period whether the estimates for sales and other non-income taxes in certain states should be revised. The expense is included in selling, general and administrative expenses on its condensed consolidated statements of operations and the liability is reflected in other current liabilities as of September 30, 2017 and December 31, 2016 , on its condensed consolidated balance sheets.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES For the periods ended September 30, 2017 and 2016 , the Company has calculated its effective tax rate based on year-to-date results (under ASC 740-270-30-18) as opposed to estimating its annual effective tax rate. The Company’s effective tax rate for the three and nine months ended September 30, 2017 was 2.2% and 10.8% , respectively, including the impact of discrete items. Excluding discrete items, the Company’s effective tax rate for the three and nine months ended September 30, 2017 was 14.9% and 21.5% , respectively. The effective tax rates are different than the statutory rates primarily due to the impact from amortization of indefinite-lived intangible assets for tax purposes, the partial non-deductibility of certain per diem expenses, and international and state taxes. The Company records valuation allowances to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment, including the long-range forecast of future taxable income and the evaluation of tax planning initiatives. Any conclusions made related to the deferred tax valuation allowance are based on a detailed evaluation of all available positive and negative evidence and the weight of such evidence. The Company believes it is necessary to see further positive evidence, such as sustained achievement of cumulative profits, before these valuation allowances can be released. Based on the Company's forecast, it is possible that the Company may release all or a portion of the remaining valuation allowance, within the next twelve months. The Company will continue to assess the realizability of its deferred tax assets. As of September 30, 2017 , the Company had approximately $0.5 million of unrecognized tax benefits included in other current liabilities and other long-term liabilities ( $5.5 million , net of deferred taxes, which would affect the effective tax rate if recognized). During the nine months ended September 30, 2017 , the Company had gross increases of $0.6 million to its current year unrecognized tax benefits related to federal and state tax issues. The tax years of 2004, 2005, 2008, and 2010 through 2016 remain open to examination by certain taxing jurisdictions to which the Company is subject to tax, other than certain states in which the statute of limitations has been extended.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2017
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS The Company provides services to hospitals which are affiliated with certain members of the Company’s Board of Directors. Management believes services with related parties were conducted on terms equivalent to those prevailing in an arm's-length transaction. Revenue related to these transactions was $1.2 million and $3.8 million for the three and nine months ended September 30, 2017 , respectively, and $1.3 million and $4.0 million for the three and nine months ended September 30, 2016 , respectively. Accounts receivable due from these hospitals at September 30, 2017 and December 31, 2016 were approximately $0.8 million and $1.0 million , respectively. In connection with the acquisition of MSN, the Company acquired a 68% ownership interest in Cross Country Talent Acquisition Group, LLC (formerly InteliStaf of Oklahoma, LLC), a joint venture between the Company and a hospital system. The Company generated revenue providing staffing services to the hospital system of $4.6 million and $13.3 million for the three and nine months ended September 30, 2017 , respectively, and $3.1 million and $9.1 million for the three and nine months ended September 30, 2016 , respectively. At September 30, 2017 and December 31, 2016 , the Company had a receivable balance of $1.7 million and $1.5 million , respectively, and a payable balance of $0.3 million and $0.2 million , respectively. Subsequent to the Company's acquisition of Mediscan on October 30, 2015, Mediscan continued to operate at premises owned, in part, by the founding members of Mediscan. The Company paid $0.1 million and $0.3 million in rent expense for these premises for the three and nine months ended September 30, 2017 and 2016.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception . The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, and should be applied retrospectively to outstanding financial instruments with a down round feature by means of either a cumulative-effect adjustment or for each prior reporting period presented. Early adoption is permitted for all entities, including adoption in an interim period. The Company expects to adopt this standard in its first quarter of 2019, and does not expect this guidance to have a material impact on its consolidated financial statements. In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718), Scope of Modification Accounting, to provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. Under this guidance, an entity should account for the effects of a modification unless all of the following are met: (1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and (3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 and is to be applied prospectively to an award modified on or after the adoption date. Early adoption is permitted. The Company expects to adopt this standard in its first quarter of 2018, and does not expect this guidance to have a material impact on its consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, to simplify how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Under this guidance, an entity would perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge would be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity would consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU 2017-04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019 and is to be applied prospectively. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company expects to early adopt this standard in 2017 in the first quarter in which an impairment test is performed, and does not expect this guidance to have a material impact on its consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business , which clarifies the definition of a business, with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This update provides a framework to assist entities in evaluating whether both an input and a substantive process are present, and narrows the definition of the term output so that the term is consistent with how outputs are described in the new revenue recognition standard. ASU 2017-01 is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. Early adoption is permitted depending upon the date of the transaction. Entities should apply the guidance prospectively on or after the effective date. No disclosures are required at transition. The Company expects to adopt this standard in its first quarter of 2018, and does not expect this guidance to have a material impact on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , which will require, among other items, lessees to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Full retrospective application is prohibited. The Company expects the valuation of right of use assets and lease liabilities, previously described as operating leases, to be the present value of our forecasted future lease commitments. The Company is continuing to assess the overall impacts of the new standard, including the discount rate to be applied in these valuations. See Note 12 - Commitments and Contingencies to the audited consolidated financial statements included in the Company's Annual Report on Form 10-K. In May 2014, the FASB and the International Accounting Standards Board jointly issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) , that introduces a new five-step revenue recognition model in which an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires disclosures sufficient to enable users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers, including qualitative and quantitative disclosures about contracts with customers, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. In March 2016, the FASB issued ASU 2016-08 which further clarifies the guidance on the principal versus agent considerations within ASU 2014-09. In April 2016, the FASB issued ASU 2016-10 to expand the guidance on identifying performance obligations and licensing within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12 to improve revenue recognition in the areas of collectability, presentation of sales tax and other similar taxes collected from customers, non-cash consideration, contract modifications and completed contracts at transition. This update also amends the disclosure requirements within ASU 2014-09 for entities that retrospectively apply the guidance. The latest amendments are intended to address implementation issues that were raised by stakeholders and discussed by the Revenue Recognition Transition Resource Group, and provide additional practical expedients. These updates are effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. The Company established a cross-functional implementation team which consisted of representatives from across all of its business segments. The initial phase of analyzing and identifying material revenue streams and the largest customers within those streams has been completed. The Company has substantially completed a thorough review of its existing contracts and business practices with its largest customers within each material revenue stream and business segment to assess the impacts of the new standard. Management will finalize the contract and business practice reviews in the fourth quarter and intends to evaluate and implement appropriate changes to its business processes, systems, and controls to support the recognition and disclosure requirements under the new standard. The Company expects to use the modified retrospective method to adopt this accounting standard and expects a full assessment through the date of adoption. Based on the steps taken to date, the Company does not expect this guidance to have a material impact on its consolidated financial statements. The Company will include the additional required disclosures regarding revenue recognition in its notes to the consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN23

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Consolidation	The accompanying condensed consolidated financial statements include the accounts of Cross Country Healthcare, Inc. and its direct and indirect wholly-owned subsidiaries (collectively, the Company). The condensed consolidated financial statements include all assets, liabilities, revenue, and expenses of Cross Country Talent Acquisition Group, LLC (formerly InteliStaf of Oklahoma, LLC), which is controlled by the Company but not wholly-owned. The Company records the ownership interest of the noncontrolling shareholder as noncontrolling interest in subsidiary. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, all entries necessary for a fair presentation of such unaudited condensed consolidated financial statements have been included. These entries consisted of all normal recurring items.
Basis of Accounting	The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. generally accepted accounting principles (U.S. GAAP) for complete financial statements. These operating results are not necessarily indicative of the results that may be expected for the year ending December 31, 2017 . These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2016 included in the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission. The December 31, 2016 condensed consolidated balance sheet included herein was derived from the December 31, 2016 audited consolidated balance sheet included in the Company’s Annual Report on Form 10-K.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Significant estimates and assumptions are used for, but not limited to: (1) the valuation of accounts receivable; (2) goodwill, trade names, and other intangible assets; (3) other long-lived assets; (4) share-based compensation; (5) accruals for health, workers’ compensation and professional liability claims; (6) valuation of deferred tax assets; (7) purchase price allocation; (8) derivative liability; (9) legal contingencies; (10) contingent considerations; (11) income taxes; and (12) sales and other non-income tax liabilities. Accrued insurance claims and reserves include estimated settlements from known claims and actuarial estimates for claims incurred but not reported. Actual results could differ from those estimates.
Recently Adopted Accounting Pronouncement	Recently Adopted Accounting Pronouncements In August 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-15, Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments , which amends the guidance in ASC 230 on the classification of certain cash receipts and payments in the statement of cash flows. This update intended to reduce the diversity that has resulted from the lack of consistent principles on this topic by adding or clarifying guidance on eight cash flow issues, including: debt prepayment or debt extinguishment costs, contingent consideration payments made after a business combination, and separately identifiable cash flows and application of the predominance principle. ASU 2016-15 is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. Early adoption was permitted. The Company elected to early adopt this standard in its first quarter of 2017, applying the guidance retrospectively with no material impact on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation-Stock Compensation (Topic 718), Improvements to Employee Share-Based Payment Accounting. The Company adopted this guidance in the first quarter of 2017. ASU 2016-09 eliminates the requirement to delay the recognition of excess tax benefits until they reduce current taxes payable. Required method of adoption is modified retrospective transition method. Upon adoption, previously unrecognized excess tax benefits of $1.3 million had no impact on the Company's accumulated deficit balance as the related deferred tax assets were fully offset by a valuation allowance. ASU 2016-09 also requires excess tax benefits and deficiencies to be recognized prospectively in the provision for income taxes rather than additional paid-in capital. As a result of the adoption, the Company's provision for income taxes was not impacted due to its full valuation allowance. Additionally, as permitted by the ASU, the Company elected to account for forfeitures as they occur rather than estimate expected forfeitures using a modified retrospective transition method. As a result, the Company recorded a cumulative-effect adjustment of $0.5 million to accumulated deficit and lower share-based compensation expense of less than $0.1 million compared to the amount of expense that would have been recorded for its first three quarters of 2017. Under ASU 2016-09, the threshold for awards to qualify for equity treatment permits withholding up to the maximum statutory tax rates in the applicable jurisdictions. Prior to the adoption of ASU 2016-09, the Company did not allow an award to be partially settled in cash in excess of the minimum statutory withholding requirements. Subsequent to the adoption of the standard, the Company will allow awards to be partially settled at the maximum applicable statutory rates. Finally, ASU 2016-09 requires excess tax benefits to be presented as a component of operating cash flows rather than financing cash flows. The Company elected to adopt this requirement prospectively and accordingly, prior periods have not been adjusted. Excess tax benefits were not material for all periods presented. In March 2016, the FASB issued ASU No. 2016-06, Derivatives and Hedging (Topic 815): Contingent Put and Call Options in Debt Instruments , to clarify the steps required to assess whether a call or put option meets the criteria for bifurcation as an embedded derivative. ASU 2016-06 is effective for interim and annual periods beginning after December 15, 2016, and requires a modified retrospective approach to adoption. The Company adopted this guidance in the first quarter of 2017. The adoption of this guidance had no impact on the Company's results of operations. RECENT ACCOUNTING PRONOUNCEMENTS In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, and II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception . The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments in Part II of this Update recharacterize the indefinite deferral of certain provisions of Topic 480 that now are presented as pending content in the Codification, to a scope exception. Those amendments do not have an accounting effect. For public business entities, the amendments in Part I of this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018, and should be applied retrospectively to outstanding financial instruments with a down round feature by means of either a cumulative-effect adjustment or for each prior reporting period presented. Early adoption is permitted for all entities, including adoption in an interim period. The Company expects to adopt this standard in its first quarter of 2019, and does not expect this guidance to have a material impact on its consolidated financial statements. In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718), Scope of Modification Accounting, to provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. Under this guidance, an entity should account for the effects of a modification unless all of the following are met: (1) the fair value of the modified award is the same as the fair value of the original award immediately before the original award is modified, (2) the vesting conditions of the modified award are the same as the vesting conditions of the original award immediately before the original award is modified, and (3) the classification of the modified award as an equity instrument or a liability instrument is the same as the classification of the original award immediately before the original award is modified. ASU 2017-09 is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 and is to be applied prospectively to an award modified on or after the adoption date. Early adoption is permitted. The Company expects to adopt this standard in its first quarter of 2018, and does not expect this guidance to have a material impact on its consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-04, Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, to simplify how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Under this guidance, an entity would perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge would be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity would consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU 2017-04 is effective for annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019 and is to be applied prospectively. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company expects to early adopt this standard in 2017 in the first quarter in which an impairment test is performed, and does not expect this guidance to have a material impact on its consolidated financial statements. In January 2017, the FASB issued ASU No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business , which clarifies the definition of a business, with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. This update provides a framework to assist entities in evaluating whether both an input and a substantive process are present, and narrows the definition of the term output so that the term is consistent with how outputs are described in the new revenue recognition standard. ASU 2017-01 is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. Early adoption is permitted depending upon the date of the transaction. Entities should apply the guidance prospectively on or after the effective date. No disclosures are required at transition. The Company expects to adopt this standard in its first quarter of 2018, and does not expect this guidance to have a material impact on its consolidated financial statements. In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) , which will require, among other items, lessees to recognize most leases as assets and liabilities on the balance sheet. Qualitative and quantitative disclosures will be enhanced to better understand the amount, timing and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years, with early adoption permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Full retrospective application is prohibited. The Company expects the valuation of right of use assets and lease liabilities, previously described as operating leases, to be the present value of our forecasted future lease commitments. The Company is continuing to assess the overall impacts of the new standard, including the discount rate to be applied in these valuations. See Note 12 - Commitments and Contingencies to the audited consolidated financial statements included in the Company's Annual Report on Form 10-K. In May 2014, the FASB and the International Accounting Standards Board jointly issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) , that introduces a new five-step revenue recognition model in which an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASU also requires disclosures sufficient to enable users to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers, including qualitative and quantitative disclosures about contracts with customers, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. In March 2016, the FASB issued ASU 2016-08 which further clarifies the guidance on the principal versus agent considerations within ASU 2014-09. In April 2016, the FASB issued ASU 2016-10 to expand the guidance on identifying performance obligations and licensing within ASU 2014-09. In May 2016, the FASB issued ASU 2016-12 to improve revenue recognition in the areas of collectability, presentation of sales tax and other similar taxes collected from customers, non-cash consideration, contract modifications and completed contracts at transition. This update also amends the disclosure requirements within ASU 2014-09 for entities that retrospectively apply the guidance. The latest amendments are intended to address implementation issues that were raised by stakeholders and discussed by the Revenue Recognition Transition Resource Group, and provide additional practical expedients. These updates are effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. The Company established a cross-functional implementation team which consisted of representatives from across all of its business segments. The initial phase of analyzing and identifying material revenue streams and the largest customers within those streams has been completed. The Company has substantially completed a thorough review of its existing contracts and business practices with its largest customers within each material revenue stream and business segment to assess the impacts of the new standard. Management will finalize the contract and business practice reviews in the fourth quarter and intends to evaluate and implement appropriate changes to its business processes, systems, and controls to support the recognition and disclosure requirements under the new standard. The Company expects to use the modified retrospective method to adopt this accounting standard and expects a full assessment through the date of adoption. Based on the steps taken to date, the Company does not expect this guidance to have a material impact on its consolidated financial statements. The Company will include the additional required disclosures regarding revenue recognition in its notes to the consolidated financial statements.

ACQUISITIONS (Tables)

ACQUISITIONS (Tables)	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
Schedule of business acquisitions	The following is the estimated fair value of the purchase price for Advantage on July 1, 2017: (amounts in thousands) Purchase price $ 88,000 Net working capital adjustments (1,438 ) Cash consideration 86,562 Cash acquired 2,833 Total funds disbursed $ 89,395
Schedule of assets acquired and liabilities assumed	The following table is an estimate of the fair value of the assets acquired and liabilities assumed on July 1, 2017. (amounts in thousands) Cash and cash equivalents $ 2,833 Accounts receivable 14,396 Other current assets 392 Property and equipment 333 Goodwill 43,596 Other intangible assets 29,900 Total assets acquired 91,450 Accounts payable and accrued expenses 368 Accrued employee compensation and benefits 1,685 Other current liabilities 2 Total liabilities assumed 2,055 Net assets acquired $ 89,395
Pro forma information	The following unaudited pro forma financial information approximates the consolidated results of operations of the Company as if the Advantage acquisition had occurred as of January 1, 2016, after giving effect to certain adjustments, including additional interest expense on the amount the Company borrowed on the date of the transaction, the amortization of acquired intangible assets, and the elimination of certain expenses that will not be recurring in post-acquisition periods, net of an estimated income tax impact. These adjustments include removing transaction-related expenses of approximately $2.0 million for the nine months ended September 30, 2017. These results are not necessarily indicative of future results as they do not include incremental investments in support functions, elimination of costs for integration or operating synergies, or an estimate of any impact on interest expense resulting from the operating cash flow of the acquired business, among other adjustments that could be made in the future but are not factually supportable on the date of the transaction. Nine Months Ended September 30, 2017 September 30, 2016 (unaudited, amounts in thousands except per share data) Revenue from services $ 696,475 $ 685,749 Net income attributable to common shareholders $ 13,165 $ 18,096 Net income per share attributable to common shareholders - Basic $ 0.38 $ 0.56 Net income per share attributable to common shareholders - Diluted $ 0.34 $ 0.02

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share	The following table sets forth the components of the numerator and denominator for the computation of the basic and diluted earnings per share: Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 (amounts in thousands, except per share data) Numerator: Net income attributable to common shareholders - Basic $ 6,723 $ 14,066 $ 9,563 $ 15,851 Interest on Convertible Notes — 853 695 2,529 Gain on derivative liability — (7,105 ) (1,581 ) (19,970 ) Net income (loss) attributable to common shareholders - Diluted $ 6,723 $ 7,814 $ 8,677 $ (1,590 ) Denominator: Weighted average common shares - Basic 35,748 32,221 34,768 32,088 Effective of diluted shares: Share-based awards 288 513 444 606 Convertible Notes — 3,521 967 3,521 Weighted average common shares - Diluted 36,036 36,255 36,179 36,215 Net income per share attributable to common shareholders - Basic $ 0.19 $ 0.44 $ 0.28 $ 0.49 Net income (loss) per share attributable to common shareholders - Diluted $ 0.19 $ 0.22 $ 0.24 $ (0.04 )

GOODWILL, TRADE NAMES, AND OT26

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Acquired Intangible Assets	The Company had the following acquired intangible assets: September 30, 2017 December 31, 2016 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount (amounts in thousands) Intangible assets subject to amortization: Databases $ 42,909 $ 17,952 $ 24,957 $ 31,609 $ 16,147 $ 15,462 Customer relationships 55,524 25,091 30,433 41,724 23,316 18,408 Non-compete agreements 3,919 3,574 345 3,619 3,527 92 Trade names 7,716 688 7,028 3,216 343 2,873 Other intangible assets, net $ 110,068 $ 47,305 $ 62,763 $ 80,168 $ 43,333 $ 36,835 Intangible assets not subject to amortization: Trade names 35,402 35,402 $ 98,165 $ 72,237
Estimated Annual Amortization Expense	As of September 30, 2017 , estimated annual amortization expense is as follows: Years Ending December 31: (amounts in thousands) 2017 $ 1,785 2018 7,168 2019 7,132 2020 7,027 2021 6,819 Thereafter 32,832 $ 62,763
Changes in Carrying Amount of Goodwill	The Company's carrying amount of goodwill by segment is as follows: Nurse Physician Other Human Total (amounts in thousands) Balances as of December 31, 2016 Aggregate goodwill acquired $ 304,277 $ 43,405 $ 9,418 $ 357,100 Accumulated impairment loss (259,732 ) (17,720 ) — (277,452 ) Goodwill, net of impairment loss 44,545 25,685 9,418 79,648 Changes to aggregate goodwill in 2017 Goodwill acquired (a) 43,596 — — 43,596 Balances as of September 30, 2017 Aggregate goodwill acquired 347,873 43,405 9,418 400,696 Accumulated impairment loss (259,732 ) (17,720 ) — (277,452 ) Goodwill, net of impairment loss $ 88,141 $ 25,685 $ 9,418 $ 123,244 _______________ (a) Goodwill acquired from the acquisition of Advantage. See Note 3 - Acquisitions.

DEBT (Tables)

DEBT (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Long-term Debt	The Applicable Margin, as of any date, is a percentage per annum determined by reference to the applicable Consolidated Net Leverage Ratio (as defined by the agreement) in effect on such date as set forth in the table below. Level Consolidated Net Leverage Ratio Eurodollar Loans, LIBOR Index Rate Loans and Letter of Credit Fee Base Rate Loans Commitment Fee I Less than 1.50:1.00 1.75% 0.75% 0.25% II Greater than or equal to 1.50:1.00 2.00% 1.00% 0.30% III Greater than or equal to 2.00:1.00 2.25% 1.25% 0.30% IV Greater than or equal to 2.50:1.00 2.50% 1.50% 0.35% V Greater than or equal to 3.00:1.00 2.75% 1.75% 0.40% The Company's long-term debt consists of the following: September 30, 2017 December 31, 2016 Principal Unamortized Discount and Debt Issuance Costs Principal Unamortized Discount and Debt Issuance Costs (amounts in thousands) Term Loan, interest 3.49% and 2.62% at September 30, 2017 and December 31, 2016, respectively $ 100,000 $ (923 ) $ 39,500 $ (363 ) Convertible Notes, fixed rate interest of 8.00% — — 25,000 (4,669 ) Convertible Notes derivative liability — — 27,532 — Capital lease obligations 12 — 23 — Total debt 100,012 (923 ) 92,055 (5,032 ) Less current portion (3,758 ) — (2,263 ) — Long-term debt $ 96,254 $ (923 ) $ 89,792 $ (5,032 )
Aggregate scheduled maturities of debt	As of September 30, 2017 , the aggregate scheduled maturities of the term loan are as follows: Term Loan (amounts in thousands) Through Years Ending December 31: 2017 $ — 2018 6,875 2019 7,500 2020 8,125 2021 10,000 Thereafter 67,500 Total $ 100,000

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Summary of Estimated Fair Values of Financial Assets and Liabilities Measured on a Recurring Basis	The table which follows summarizes the estimated fair value of the Company’s financial assets and liabilities measured on a recurring basis: Fair Value Measurements September 30, 2017 December 31, 2016 Financial Liabilities: (amounts in thousands) (Level 1) Deferred compensation $ 1,381 $ 1,472 (Level 3) Convertible Notes derivative liability $ — $ 27,532 Contingent consideration liabilities $ 5,269 $ 5,603
Schedule of reconciliation of opening and closing balances for fair value measurements categorized within Level 3	The table which follows reconciles the opening balances to the closing balances for fair value measurements categorized within Level 3 of the fair value hierarchy: Contingent Consideration Convertible Notes Liabilities (a) Derivative Liability (amounts in thousands) December 31, 2016 $ 5,603 $ 27,532 Payments/Settlements (100 ) (25,951 ) Accretion expense 270 — Valuation gain for the period — (1,581 ) March 31, 2017 5,773 — Accretion expense 281 — June 30, 2017 $ 6,054 $ — Payments (180 ) — Accretion expense 209 — Valuation adjustment (814 ) — September 30, 2017 $ 5,269 $ — _______________ (a) Related to the Mediscan acquisition on October 30, 2015 and the USR acquisition on December 1, 2016. Valuation adjustments and accretion expense is included as acquisition-related contingent consideration on the condensed consolidated statements of operations.
Carrying Amounts and Estimated Fair Values of Significant Financial Instrument that were not Measured at Fair Value	The following table represents the carrying amounts and estimated fair value of the Company’s significant financial instruments that were not measured at fair value: September 30, 2017 December 31, 2016 Carrying Fair Carrying Fair Financial Liabilities: (amounts in thousands) (Level 2) Term Loan, net $ 99,077 $ 101,000 $ 39,137 $ 41,500 Convertible Notes, net $ — $ — $ 20,331 $ 27,250

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Summary of Restricted Stock Activity	The following table summarizes restricted stock awards and performance stock awards activity issued under the 2014 Plan for the nine months ended September 30, 2017 : Restricted Stock Awards Performance Stock Awards Number of Weighted Number of Target Weighted Unvested restricted stock awards, January 1, 2017 532,294 $ 9.98 332,092 $ 11.73 Granted 323,503 $ 13.70 181,067 $ 14.36 Vested (292,615 ) $ 8.64 — $ — Forfeited (47,581 ) $ 10.41 (131,016 ) $ 11.78 Unvested restricted stock awards, September 30, 2017 515,601 $ 13.03 382,143 $ 12.96

SEGMENT DATA (Tables)

SEGMENT DATA (Tables)	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Information on Operating Segments and Reconciliation to Loss From Operations	Information on operating segments and a reconciliation to income (loss) from operations for the periods indicated are as follows: Three Months Ended Nine Months Ended September 30, September 30, 2017 2016 2017 2016 (amounts in thousands) Revenues: Nurse and Allied Staffing $ 200,492 $ 186,623 $ 564,527 $ 527,436 Physician Staffing 24,871 25,090 71,055 73,470 Other Human Capital Management Services 3,125 3,275 9,792 10,108 $ 228,488 $ 214,988 $ 645,374 $ 611,014 Contribution income: Nurse and Allied Staffing $ 20,663 $ 19,472 $ 54,426 $ 53,877 Physician Staffing 1,340 2,400 4,207 6,003 Other Human Capital Management Services (1 ) (154 ) (200 ) (196 ) 22,002 21,718 58,433 59,684 Unallocated corporate overhead 9,301 9,449 30,414 29,608 Depreciation and amortization 2,849 2,092 7,325 6,969 Acquisition-related contingent consideration (605 ) 237 (54 ) 707 Acquisition and integration costs 1,366 — 1,953 — Restructuring costs 724 611 724 611 Impairment charges — — — 24,311 Income (loss) from operations $ 8,367 $ 9,329 $ 18,071 $ (2,522 )

SUMMARY OF SIGNIFICANT ACCOUN31

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Jan. 01, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Restructuring charges	$ 724	$ 611	$ 724	$ 611
Accounting Standards Update 2016-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred tax assets					$ 1,300
Valuation allowance					1,300
Share-based compensation			100
Accumulated Deficit [Member] | Accounting Standards Update 2016-09, Forfeiture Rate Component [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect adjustment					$ 500
Cost Optimization Project [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Restructuring charges	700		700
Restructuring liability	600		600
Post Employment Benefits [Member] | Cost Optimization Project [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Restructuring charges	500		500
Payments for restructuring	0		0
Restructuring liability	400		400
Post Employment Benefits [Member] | Prior Initiative [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Restructuring liability	200		200
Exit Liabilities [Member] | Cost Optimization Project [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Restructuring charges	200		200
Restructuring liability	$ 200		$ 200

ACQUISITIONS - Advantage RN (De

ACQUISITIONS - Advantage RN (Details) - USD ($) $ in Thousands	Jul. 28, 2017	Jul. 01, 2017	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Business Acquisition [Line Items]
Cash consideration					$ 85,977	$ 0
Borrowings on debt					62,000	40,000
Acquisition related costs			$ 1,366	$ 0	1,953	$ 0
Advantage RN, LLC [Member]
Business Acquisition [Line Items]
Cash consideration		$ 86,562
Net working capital adjustment		600
Reimbursement from working capital adjustment settled			800
Contingent liability			300		$ 300
Release of remaining contingent liability			300
Escrow payment related to tax liabilities		14,500
Escrow payment related to post-close liabilities		7,500
Release of escrow to seller	$ 7,300
Escrow deposit related to tax liabilities	$ 7,200
Consideration transferred, available cash		19,900
Revenue since acquisition			24,500
Net income since acquisition			2,100
Assets acquired		$ 29,900
Weighted average useful life of assets acquired		10 years
Goodwill expected to be deductible		$ 43,600
Acquisition related costs			$ 1,400
Trade names [Member] | Advantage RN, LLC [Member]
Business Acquisition [Line Items]
Assets acquired		$ 4,500
Weighted average useful life of assets acquired		10 years
Customer relationships [Member] | Advantage RN, LLC [Member]
Business Acquisition [Line Items]
Assets acquired		$ 13,800
Weighted average useful life of assets acquired		10 years
Databases [Member] | Advantage RN, LLC [Member]
Business Acquisition [Line Items]
Assets acquired		$ 11,300
Weighted average useful life of assets acquired		10 years
Non-compete agreements [Member] | Advantage RN, LLC [Member]
Business Acquisition [Line Items]
Assets acquired		$ 300
Weighted average useful life of assets acquired		5 years
Deferred Consideration Transferred [Member] | Advantage RN, LLC [Member]
Business Acquisition [Line Items]
Contingent liability		$ 600
Period of deferred consideration		20 months
Credit Agreement [Member]
Business Acquisition [Line Items]
Borrowings on debt		$ 66,900
Term Loan [Member] | Incremental Term Loan [Member]
Business Acquisition [Line Items]
Borrowings on debt		40,000
Physician Staffing [Member] | Advantage RN, LLC [Member]
Business Acquisition [Line Items]
Percentage of results aggregated into segment, less than			2.00%		2.00%
Purchase Price [Member] | Advantage RN, LLC [Member]
Business Acquisition [Line Items]
Purchase price		$ 88,000

ACQUISITIONS - Fair Value of Pu

ACQUISITIONS - Fair Value of Purchase Price (Details) - USD ($) $ in Thousands	Jul. 01, 2017	Sep. 30, 2017	Sep. 30, 2016
Business Acquisition [Line Items]
Cash consideration		$ 85,977	$ 0
Total funds disbursed		$ 239	$ 1,858
Advantage RN, LLC [Member]
Business Acquisition [Line Items]
Cash consideration	$ 86,562
Cash acquired	2,833
Total funds disbursed	89,395
Purchase Price [Member] | Advantage RN, LLC [Member]
Business Acquisition [Line Items]
Purchase price	88,000
Net Working Capital Adjustments [Member] | Advantage RN, LLC [Member]
Business Acquisition [Line Items]
Purchase price	$ (1,438)

ACQUISITIONS - Assets Acquired

ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Jul. 01, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill	$ 123,244		$ 79,648
Advantage RN, LLC [Member]
Business Acquisition [Line Items]
Cash and cash equivalents		$ 2,833
Accounts receivable		14,396
Other current assets		392
Property and equipment		333
Goodwill		43,596
Other intangible assets		29,900
Total assets acquired		91,450
Accounts payable and accrued expenses		368
Accrued employee compensation and benefits		1,685
Other current liabilities		2
Total liabilities assumed		2,055
Net assets acquired		$ 89,395

ACQUISITIONS - Narrative (Detai

ACQUISITIONS - Narrative (Details) - USD ($) $ in Thousands

May 03, 2017

Jun. 30, 2014

Sep. 30, 2017

Sep. 30, 2016

Mar. 31, 2016

Sep. 30, 2017

Sep. 30, 2016

Mar. 31, 2016

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Dec. 01, 2016

Apr. 01, 2016

Oct. 30, 2015

Business Acquisition [Line Items]

Consolidated net income

$ 7,044

$ 14,289

$ 10,546

$ 16,380

US Resources Healthcare, LLC [Member]

Business Acquisition [Line Items]

Contingent consideration, range of outcomes, high

$ 4,500

Mediscan [Member]

Business Acquisition [Line Items]

Net working capital adjustment

$ 300

Release of escrow to seller

$ 5,000

Contingent consideration, range of outcomes, high

$ 7,000

Medical Staffing Network [Member]

Business Acquisition [Line Items]

Contingent consideration liabilities

$ 2,100

Release of remaining contingent liability

$ 400

Potential Earnout, Attainment of Specific Performance Criteria in 2017 [Member] | US Resources Healthcare, LLC [Member]

Business Acquisition [Line Items]

Contingent consideration, range of outcomes, high

1,000

Potential Earnout, Attainment of Specific Performance Criteria in 2017 [Member] | Mediscan [Member]

Business Acquisition [Line Items]

Contingent consideration, range of outcomes, high

3,500

Potential Earnout, Attainment of Specific Performance Criteria in 2018 [Member] | US Resources Healthcare, LLC [Member]

Business Acquisition [Line Items]

Contingent consideration, range of outcomes, high

2,000

Potential Earnout, Attainment of Specific Performance Criteria in 2019 [Member] | US Resources Healthcare, LLC [Member]

Business Acquisition [Line Items]

Contingent consideration, range of outcomes, high

$ 1,500

Potential Earnout, Attainment of Specific Performance Criteria in 2016 [Member] | Mediscan [Member]

Business Acquisition [Line Items]

Contingent consideration, range of outcomes, high

$ 3,500

Assumed Additional Contingent Purchase Price Liabilities [Member] | US Resources Healthcare, LLC [Member]

Business Acquisition [Line Items]

Contingent consideration liabilities

1,500

1,500

Assumed Additional Contingent Purchase Price Liabilities [Member] | Mediscan [Member]

Business Acquisition [Line Items]

Contingent consideration, range of outcomes, high

$ 300

Contingent liability paid

300

Contingent consideration liabilities

$ 3,800

3,800

Deferred Consideration Transferred [Member] | Medical Staffing Network [Member]

Business Acquisition [Line Items]

Contingent consideration liabilities

$ 2,500

Period of deferred consideration

21 months

Forecast [Member] | Assumed Additional Contingent Purchase Price Liabilities [Member] | Mediscan [Member]

Business Acquisition [Line Items]

Contingent consideration, range of outcomes, high

$ 300

$ 300

Acquisition-related Costs [Member]

Business Acquisition [Line Items]

Consolidated net income

$ 2,000

ACQUISITIONS - Pro Forma (Detai

ACQUISITIONS - Pro Forma (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Business Combinations [Abstract]
Revenue from services	$ 696,475	$ 685,749
Net income attributable to common shareholders	$ 13,165	$ 18,096
Net income per share attributable to common shareholders - Basic (in dollars per share)	$ 0.38	$ 0.56
Net income per share attributable to common shareholders - Diluted (in dollars per share)	$ 0.34	$ 0.02

EARNINGS PER SHARE - Components

EARNINGS PER SHARE - Components of Numerator and Denominator for Computation of Basic and Diluted Earnings per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Numerator:
Net income attributable to common shareholders - Basic	$ 6,723	$ 14,066	$ 9,563	$ 15,851
Interest on Convertible Notes	0	853	695	2,529
Gain on derivative liability	0	(7,105)	(1,581)	(19,970)
Net income (loss) attributable to common shareholders - Diluted	$ 6,723	$ 7,814	$ 8,677	$ (1,590)
Denominator:
Weighted average common shares - Basic (shares)	35,748,000	32,221,000	34,768,000	32,088,000
Effective of diluted shares:
Share-based awards (shares)	288,000	513,000	444,000	606,000
Convertible Notes (shares)	0	3,521,126	967,342	3,521,126
Weighted average common shares - Diluted (shares)	36,036,000	36,255,000	36,179,000	36,215,000
Net income per share attributable to common shareholders - Basic (in dollars per share)	$ 0.19	$ 0.44	$ 0.28	$ 0.49
Net income (loss) per share attributable to common shareholders - Diluted (in dollars per share)	$ 0.19	$ 0.22	$ 0.24	$ (0.04)

COMPREHENSIVE INCOME (LOSS) (De

COMPREHENSIVE INCOME (LOSS) (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Equity [Abstract]
Loss on currency fluctuations	$ 1,200,000		$ 1,200,000		$ 1,200,000
Income tax impact related to foreign currency translation adjustments	$ 0	$ 0	$ 0	$ 0

GOODWILL, TRADE NAMES, AND OT39

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Acquired Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 110,068	$ 80,168
Accumulated Amortization	47,305	43,333
Intangible assets subject to amortization, net carrying amount	62,763	36,835
Trade names	35,402	35,402
Total intangible assets, net	98,165	72,237
Databases [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	42,909	31,609
Accumulated Amortization	17,952	16,147
Intangible assets subject to amortization, net carrying amount	24,957	15,462
Customer relationships [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	55,524	41,724
Accumulated Amortization	25,091	23,316
Intangible assets subject to amortization, net carrying amount	30,433	18,408
Non-compete agreements [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	3,919	3,619
Accumulated Amortization	3,574	3,527
Intangible assets subject to amortization, net carrying amount	345	92
Trade names [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	7,716	3,216
Accumulated Amortization	688	343
Intangible assets subject to amortization, net carrying amount	$ 7,028	$ 2,873

GOODWILL, TRADE NAMES, AND OT40

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Annual Amortization Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
2,017	$ 1,785
2,018	7,168
2,019	7,132
2,020	7,027
2,021	6,819
Thereafter	32,832
Intangible assets subject to amortization, net carrying amount	$ 62,763	$ 36,835

GOODWILL, TRADE NAMES, AND OT41

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Goodwill Rollforward (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Goodwill [Roll Forward]
Goodwill, net of impairment loss, beginning period	$ 79,648
Changes to aggregate goodwill in 2017
Goodwill, net of impairment loss, ending period	123,244
Operating Segments [Member]
Goodwill [Roll Forward]
Aggregate goodwill acquired, beginning period	357,100
Accumulated impairment loss, beginning period	(277,452)
Goodwill, net of impairment loss, beginning period	79,648
Changes to aggregate goodwill in 2017
Goodwill acquired	43,596
Aggregate goodwill acquired, ending period	400,696
Accumulated impairment loss, ending period	(277,452)
Goodwill, net of impairment loss, ending period	123,244
Operating Segments [Member] | Nurse And Allied Staffing [Member]
Goodwill [Roll Forward]
Aggregate goodwill acquired, beginning period	304,277
Accumulated impairment loss, beginning period	(259,732)
Goodwill, net of impairment loss, beginning period	44,545
Changes to aggregate goodwill in 2017
Goodwill acquired	43,596
Aggregate goodwill acquired, ending period	347,873
Accumulated impairment loss, ending period	(259,732)
Goodwill, net of impairment loss, ending period	88,141
Operating Segments [Member] | Physician Staffing [Member]
Goodwill [Roll Forward]
Aggregate goodwill acquired, beginning period	43,405
Accumulated impairment loss, beginning period	(17,720)
Goodwill, net of impairment loss, beginning period	25,685
Changes to aggregate goodwill in 2017
Goodwill acquired	0
Aggregate goodwill acquired, ending period	43,405
Accumulated impairment loss, ending period	(17,720)
Goodwill, net of impairment loss, ending period	25,685
Operating Segments [Member] | Other Human Capital Management Services [Member]
Goodwill [Roll Forward]
Aggregate goodwill acquired, beginning period	9,418
Accumulated impairment loss, beginning period	0
Goodwill, net of impairment loss, beginning period	9,418
Changes to aggregate goodwill in 2017
Goodwill acquired	0
Aggregate goodwill acquired, ending period	9,418
Accumulated impairment loss, ending period	0
Goodwill, net of impairment loss, ending period	$ 9,418

GOODWILL, TRADE NAMES, AND OT42

GOODWILL, TRADE NAMES, AND OTHER INTANGIBLE ASSETS - Additional Information (Details) - USD ($)	Jun. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Impairment charges		$ 0	$ 0	$ 0	$ 24,311,000	$ 0
Physician Staffing [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment charges	$ 24,300,000
Goodwill impairment charge	17,700,000
Customer relationships [Member] | Physician Staffing [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangibles finite lived	6,000,000
Trade names [Member] | Physician Staffing [Member]
Finite-Lived Intangible Assets [Line Items]
Impairment of intangibles indefinite lived	$ 600,000

DEBT - Long- Term Debt (Details

DEBT - Long- Term Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Mar. 17, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Capital lease obligations	$ 12		$ 23
Total debt	100,012		92,055
Less current portion	(3,758)		(2,263)
Long-term Debt and Capital Lease Obligations	96,254		89,792
Unamortized Discount and Debt Issuance Costs	(923)		(5,032)
Senior Debt [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Debt	100,000		39,500
Unamortized Discount and Debt Issuance Costs	$ (923)		$ (363)
Interest Rate	3.49%		2.62%
Convertible Notes [Member]
Debt Instrument [Line Items]
Interest Rate		8.00%
Convertible Notes [Member] | 8% Convertible Notes [Member]
Debt Instrument [Line Items]
Debt	$ 0		$ 25,000
Unamortized Discount and Debt Issuance Costs	$ 0		(4,669)
Interest Rate	8.00%
Convertible Notes [Member] | Convertible Note Derivative Liability [Member]
Debt Instrument [Line Items]
Debt	$ 0		27,532
Unamortized Discount and Debt Issuance Costs	$ 0		$ 0

DEBT - Debt Maturities (Details

DEBT - Debt Maturities (Details) - Term Loan [Member] $ in Thousands	Sep. 30, 2017USD ($)
Long-term Debt, Fiscal Year Maturity [Abstract]
2,017	$ 0
2,018	6,875
2,019	7,500
2,020	8,125
2,021	10,000
Thereafter	67,500
Total	$ 100,000

DEBT - Amendment And Restatemen

DEBT - Amendment And Restatement Of Senior Credit Facility (Details)	Aug. 01, 2017USD ($)	Sep. 30, 2017USD ($)financial_covenant	Sep. 30, 2016USD ($)
Debt Instrument [Line Items]
Borrowings on debt		$ 62,000,000	$ 40,000,000
Amended And Restated Credit Agreement [Member]
Debt Instrument [Line Items]
Face amount	$ 215,000,000
Sub facility for swingline loans	15,000,000
Line of credit, subfacility for standby letters of credit	35,000,000
Borrowings on debt	106,500,000
Interest rate increase (decrease) (percent)		2.00%
Quarterly commitment fee on the average daily unused portion (percent)		0.30%
Number of financial covenants | financial_covenant		2
Amended And Restated Credit Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Consolidated Fixed Charge Coverage Ratio		1.50
Amended And Restated Credit Agreement [Member] | Fiscal Quarters Ending September 30, 2017 through June 30, 2018 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Consolidated Total Leverage Ratio		3.50
Amended And Restated Credit Agreement [Member] | Fiscal Quarters Ending September 30, 2018 through June 30, 2019 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Consolidated Total Leverage Ratio		3.25
Amended And Restated Credit Agreement [Member] | Each Fiscal Quarter Ending Thereafter [Member] | Maximum [Member]
Debt Instrument [Line Items]
Consolidated Total Leverage Ratio		3
Term Loan [Member] | Amended And Restated Credit Agreement [Member]
Debt Instrument [Line Items]
Face amount	100,000,000
Additional capacity	$ 50,000,000
Term Loan [Member] | Amended And Restated Credit Agreement [Member] | First Four Installments [Member]
Debt Instrument [Line Items]
Periodic payment, percentage of principal	5.00%
Term Loan [Member] | Amended And Restated Credit Agreement [Member] | Next Eight Installments [Member]
Debt Instrument [Line Items]
Periodic payment, percentage of principal	7.50%
Term Loan [Member] | Amended And Restated Credit Agreement [Member] | Remaining Installments [Member]
Debt Instrument [Line Items]
Periodic payment, percentage of principal	10.00%
Revolving Credit Facility [Member] | Amended And Restated Credit Agreement [Member]
Debt Instrument [Line Items]
Letters of credit outstanding		$ 21,600,000
Line of credit outstanding		$ 93,400,000
Revolving Credit Facility [Member] | Amended And Restated Credit Agreement [Member] | LIBOR [Member]
Debt Instrument [Line Items]
Interest margin		2.25%
Revolving Credit Facility [Member] | Line of Credit [Member] | Amended And Restated Credit Agreement [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 115,000,000
Borrowings on debt	$ 6,500,000

DEBT - Consolidated Net Leverag

DEBT - Consolidated Net Leverage Ratio (Details) - Credit Agreement [Member]	Jul. 05, 2017	Sep. 30, 2017
Covenant Term 1 [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage		0.25%
Covenant Term 1 [Member] | Eurodollar Loans [Member]
Line of Credit Facility [Line Items]
Interest margin		1.75%
Covenant Term 1 [Member] | LIBOR Index Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin		1.75%
Covenant Term 1 [Member] | Letter of Credit Fee [Member]
Line of Credit Facility [Line Items]
Interest margin		1.75%
Covenant Term 1 [Member] | Base Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin		0.75%
Covenant Term 1 [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio		1.50
Covenant Term 2 [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage		0.30%
Covenant Term 2 [Member] | Eurodollar Loans [Member]
Line of Credit Facility [Line Items]
Interest margin		2.00%
Covenant Term 2 [Member] | LIBOR Index Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin		2.00%
Covenant Term 2 [Member] | Letter of Credit Fee [Member]
Line of Credit Facility [Line Items]
Interest margin		2.00%
Covenant Term 2 [Member] | Base Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin		1.00%
Covenant Term 2 [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio		1.50
Covenant Term 2 [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio		2
Covenant Term 3 [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage	0.30%	0.30%
Covenant Term 3 [Member] | Eurodollar Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	2.25%	2.25%
Covenant Term 3 [Member] | LIBOR Index Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin		2.25%
Covenant Term 3 [Member] | Letter of Credit Fee [Member]
Line of Credit Facility [Line Items]
Interest margin		2.25%
Covenant Term 3 [Member] | Base Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin	1.25%	1.25%
Covenant Term 3 [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio		2
Covenant Term 3 [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio		2.50
Covenant Term 4 [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage		0.35%
Covenant Term 4 [Member] | Eurodollar Loans [Member]
Line of Credit Facility [Line Items]
Interest margin		2.50%
Covenant Term 4 [Member] | LIBOR Index Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin		2.50%
Covenant Term 4 [Member] | Letter of Credit Fee [Member]
Line of Credit Facility [Line Items]
Interest margin		2.50%
Covenant Term 4 [Member] | Base Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin		1.50%
Covenant Term 4 [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio		2.50
Covenant Term 4 [Member] | Maximum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio		3
Covenant Term 5 [Member]
Line of Credit Facility [Line Items]
Commitment fee percentage		0.40%
Covenant Term 5 [Member] | Eurodollar Loans [Member]
Line of Credit Facility [Line Items]
Interest margin		2.75%
Covenant Term 5 [Member] | LIBOR Index Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin		2.75%
Covenant Term 5 [Member] | Letter of Credit Fee [Member]
Line of Credit Facility [Line Items]
Interest margin		2.75%
Covenant Term 5 [Member] | Base Rate Loans [Member]
Line of Credit Facility [Line Items]
Interest margin		1.75%
Covenant Term 5 [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Consolidated Net Leverage Ratio		3

DEBT - 2016 Senior Credit Facil

DEBT - 2016 Senior Credit Facilities (Details) - USD ($)	Jul. 05, 2017	Jun. 22, 2016	Sep. 30, 2017	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Debt Instrument [Line Items]
Prepayment penalty		$ 600,000
Loss on early extinguishment of debt			$ 0	$ 0		$ 4,969,000	$ 1,568,000
Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Loss on early extinguishment of debt					$ 1,600,000
Senior Debt [Member] | Credit Agreement [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity		40,000,000
Term Loan [Member] | Incremental Term Loan [Member]
Debt Instrument [Line Items]
Face amount	$ 40,000,000
Term Loan [Member] | Incremental Term Loan [Member] | First Eight Installments [Member]
Debt Instrument [Line Items]
Periodic payment, percentage of principal	1.875%
Term Loan [Member] | Incremental Term Loan [Member] | Remaining Installments [Member]
Debt Instrument [Line Items]
Periodic payment, percentage of principal	2.50%
Term Loan [Member] | Incremental Term Loan [Member] | Eurodollar [Member]
Debt Instrument [Line Items]
Interest margin	2.25%
Term Loan [Member] | Incremental Term Loan [Member] | Base Rate Loans [Member]
Debt Instrument [Line Items]
Interest margin	1.25%
Revolving Credit Facility [Member] | Credit Agreement [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity		100,000,000
Sub facility for swingline loans		15,000,000
Line of credit, subfacility for standby letters of credit		$ 35,000,000
Covenant Term 3 [Member] | Credit Agreement [Member]
Debt Instrument [Line Items]
Commitment fee percentage	0.30%					0.30%
Covenant Term 3 [Member] | Credit Agreement [Member] | Eurodollar [Member]
Debt Instrument [Line Items]
Interest margin	2.25%					2.25%
Covenant Term 3 [Member] | Credit Agreement [Member] | Base Rate Loans [Member]
Debt Instrument [Line Items]
Interest margin	1.25%					1.25%

DEBT - Private Placement of Con

DEBT - Private Placement of Convertible Notes Narrative (Details)	Mar. 17, 2017USD ($)dayinstrument$ / sharesshares	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Jun. 30, 2014USD ($)
Debt Instrument [Line Items]
Repayments of debt				$ 1,500,000	$ 30,500,000
Extinguishment fees				578,000	641,000
Loss on early extinguishment of debt		$ 0	$ 0	$ 4,969,000	$ 1,568,000
Convertible Notes [Member]
Debt Instrument [Line Items]
Face amount						$ 25,000,000
Common stock, par value (in usd per share) | $ / shares	$ 0.0001
Payment of debt and extinguishment fees	$ 5,600,000
Repayments of debt	5,000,000
Extinguishment fees	600,000
Loss on early extinguishment of debt	5,000,000
Non-cash write off related to settlement of convertible notes	$ 46,000,000
Debt conversion price (in usd per share) | $ / shares	$ 7.10
Debt instrument, convertible, number of equity instruments | instrument	3,521,126
Debt Instrument, convertible, threshold period following issuance date (in years)	3 years
Debt instrument, convertible, threshold percentage of stock price trigger	125.00%
Debt instrument, convertible, threshold trading days | day	20
Debt instrument, convertible, threshold consecutive trading days	30 days
Interest rate (percent)	8.00%
Common Stock [Member]
Debt Instrument [Line Items]
Shares issued (in shares) | shares	3,175,584
8% Convertible Notes [Member] | Convertible Notes [Member]
Debt Instrument [Line Items]
Original debt amount in debt conversion	$ 20,000,000
Interest rate (percent)		8.00%		8.00%
Convertible Note Derivative Liability [Member] | Convertible Notes [Member]
Debt Instrument [Line Items]
Original debt amount in debt conversion	$ 26,000,000

DEBT - Prior Credit Facilities

DEBT - Prior Credit Facilities (Details) - Revolving Credit Facility [Member]	12 Months Ended
	Dec. 31, 2015USD ($)
First Lien Loan Agreement [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 85,000,000
Borrowing availability as percentage of commitments	10.00%
Line of credit, subfacility for standby letters of credit	$ 35,000,000
Subordinated Debt [Member] | Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 30,000,000
Debt term	5 years
Subordinated Debt [Member] | Second Lien Term Loan [Member] | Period One [Member]
Debt Instrument [Line Items]
Percentage of principal amount redeemed	103.00%
Subordinated Debt [Member] | Second Lien Term Loan [Member] | Period Two [Member]
Debt Instrument [Line Items]
Percentage of principal amount redeemed	102.00%
Subordinated Debt [Member] | Second Lien Term Loan [Member] | Period Three [Member]
Debt Instrument [Line Items]
Percentage of principal amount redeemed	100.00%

FAIR VALUE MEASUREMENTS - Estim

FAIR VALUE MEASUREMENTS - Estimated Fair values Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Fair Value, Inputs, Level 1 [Member] | Deferred compensation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Deferred compensation	$ 1,381	$ 1,472
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liabilities	5,269	5,603
Fair Value, Inputs, Level 3 [Member] | Convertible Notes, Derivative Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Convertible Notes derivative liability	$ 0	$ 27,532

FAIR VALUE MEASUREMENTS - Sched

FAIR VALUE MEASUREMENTS - Schedule of reconciliation of opening and closing balances for fair value measurements categorized within Level 3 (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017
Contingent Consideration Liabilities [Member]
Convertible Note Derivative Liability
Beginning balance	$ 6,054	$ 5,773	$ 5,603
Payments/Settlements	(180)		(100)
Accretion expense	209	281	270
Valuation gain for the period	814		0
Ending balance	5,269	6,054	5,773
Convertible Notes Derivative Liability [Member]
Convertible Note Derivative Liability
Beginning balance	0	0	27,532
Payments/Settlements	0		(25,951)
Accretion expense	0	0	0
Valuation gain for the period	0		(1,581)
Ending balance	$ 0	$ 0	$ 0

FAIR VALUE MEASUREMENTS - Narra

FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Fair Value Measurement [Line Items]
Impairment charges	$ 0	$ 0	$ 0	$ 24,311,000	$ 0
Minimum [Member]
Fair Value Measurement [Line Items]
Threshold period, past due for payment of services provided			15 days
Maximum [Member]
Fair Value Measurement [Line Items]
Threshold period, past due for payment of services provided			60 days

FAIR VALUE MEASUREMENTS - Finan

FAIR VALUE MEASUREMENTS - Financial Instrument that were not Measured at Fair Value (Details) - Fair Value, Inputs, Level 2 [Member] - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Term Loan, Net [Member] | Reported Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Carrying Amount	$ 99,077	$ 39,137
Term Loan, Net [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Fair Value	101,000	41,500
Convertible Notes, Net [Member] | Reported Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Carrying Amount	0	20,331
Convertible Notes, Net [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Option, Quantitative Disclosures [Line Items]
Financial Liabilities, Fair Value	$ 0	$ 27,250

STOCKHOLDERS' EQUITY - Narrativ

STOCKHOLDERS' EQUITY - Narrative (Details) - USD ($)	May 23, 2017	Mar. 17, 2017	Sep. 30, 2017	Mar. 31, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares of common stock outstanding			35,758,297			35,758,297
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation			$ 1,100,000		$ 800,000	$ 3,100,000	$ 2,600,000
Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares available for grant (in shares)	2,000,000
Aggregate share reserve (up to)	6,100,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)						323,503
Vested in period, net (in shares)			3,110		9,742	204,786	225,107
Restricted Stock [Member] | Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)						323,503
Vesting period						3 years
Performance Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)						181,067
Performance Stock [Member] | Omnibus Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)						181,067
Level of performance attained and approved (percent)				48.00%
Shares issued in period				86,784
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued (in shares)		3,175,584
February 2008 Board Authorization [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares repurchased (in shares)						0	0
Common shares left remaining to repurchase under the plan (up to)			942,443			942,443
Stock repurchase program, authorized amount (up to)			$ 2,500,000			$ 2,500,000

STOCKHOLDERS' EQUITY - Summary

STOCKHOLDERS' EQUITY - Summary of Restricted Stock and Performance Shares (Details)	9 Months Ended
	Sep. 30, 2017$ / sharesshares
Restricted Stock [Member]
Number of Shares
Unvested restricted stock awards, Beginning balance (in shares) | shares	532,294
Granted (in shares) | shares	323,503
Vested (in shares) | shares	(292,615)
Forfeited (in shares) | shares	(47,581)
Unvested restricted stock awards, Ending balance (in shares) | shares	515,601
Weighted Average Grant Date Fair Value (in usd per share)
Unvested restricted stock awards, Beginning balance (in dollars per share) | $ / shares	$ 9.98
Granted (in dollars per share) | $ / shares	13.70
Vested (in dollars per share) | $ / shares	8.64
Forfeited (in dollars per share) | $ / shares	10.41
Unvested restricted stock awards, Ending balance (in dollars per share) | $ / shares	$ 13.03
Performance Stock [Member]
Number of Shares
Unvested restricted stock awards, Beginning balance (in shares) | shares	332,092
Granted (in shares) | shares	181,067
Vested (in shares) | shares	0
Forfeited (in shares) | shares	(131,016)
Unvested restricted stock awards, Ending balance (in shares) | shares	382,143
Weighted Average Grant Date Fair Value (in usd per share)
Unvested restricted stock awards, Beginning balance (in dollars per share) | $ / shares	$ 11.73
Granted (in dollars per share) | $ / shares	14.36
Vested (in dollars per share) | $ / shares	0
Forfeited (in dollars per share) | $ / shares	11.78
Unvested restricted stock awards, Ending balance (in dollars per share) | $ / shares	$ 12.96

SEGMENT DATA - Narrative (Detai

SEGMENT DATA - Narrative (Details)	9 Months Ended
	Sep. 30, 2017segment
Segment Reporting Information [Line Items]
Number of operating segments	3
Advantage RN, LLC [Member] | Physician Staffing [Member]
Segment Reporting Information [Line Items]
Percentage of results aggregated into segment, less than	2.00%

SEGMENT DATA - Information on O

SEGMENT DATA - Information on Operating Segments and Reconciliation to Loss From Operations (Details) - USD ($)	Jun. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues		$ 228,488,000	$ 214,988,000	$ 645,374,000	$ 611,014,000
Contribution income		22,002,000	21,718,000	58,433,000	59,684,000
Unallocated corporate overhead		9,301,000	9,449,000	30,414,000	29,608,000
Depreciation and amortization		2,849,000	2,092,000	7,325,000	6,969,000
Acquisition-related contingent consideration		(605,000)	237,000	(54,000)	707,000
Acquisition and integration costs		1,366,000	0	1,953,000	0
Restructuring costs		724,000	611,000	724,000	611,000
Impairment charges		0	0	0	24,311,000	$ 0
Income (loss) from operations		8,367,000	9,329,000	18,071,000	(2,522,000)
Nurse and allied staffing [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues		200,492,000	186,623,000	564,527,000	527,436,000
Contribution income		20,663,000	19,472,000	54,426,000	53,877,000
Physician staffing [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues		24,871,000	25,090,000	71,055,000	73,470,000
Contribution income		1,340,000	2,400,000	4,207,000	6,003,000
Impairment charges	$ 24,300,000
Other human capital management services [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Revenues		3,125,000	3,275,000	9,792,000	10,108,000
Contribution income		$ (1,000)	$ (154,000)	$ (200,000)	$ (196,000)

INCOME TAXES (Details)

INCOME TAXES (Details) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2017USD ($)	Sep. 30, 2017USD ($)
Income Tax Disclosure [Abstract]
Effective tax rate (percentage)	2.20%	10.80%
Effective income tax rate continuing operations excluding discrete items (percentage)	14.90%	21.50%
Unrecognized tax benefits	$ 0.5	$ 0.5
Unrecognized tax benefits that would impact effective tax rate	$ 5.5	5.5
Gross increase to current year unrecognized tax benefits related to federal and state tax issues		$ 0.6

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Related Party Transaction [Line Items]
Revenue from related parties	$ 1.2	$ 1.3	$ 3.8	$ 4
Accounts receivable	0.8		0.8		$ 1
InteliStaf [Member]
Related Party Transaction [Line Items]
Revenue from related parties	$ 4.6	3.1	$ 13.3	9.1
Joint venture, percent ownership	68.00%		68.00%
Receivable balance with joint venture	$ 1.7		$ 1.7		1.5
Payable balance with joint venture	0.3		0.3		$ 0.2
Affiliated Entity [Member]
Related Party Transaction [Line Items]
Rent expense	$ 0.1	$ 0.1	$ 0.3	$ 0.3